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Abstract 
Atherosclerosis is a primary cause of heart disease and stroke. It is known that 
early detection of atherosclerotic lesions would significantly reduce the risk. One of the 
objectives in this thesis is to evaluate a noninvasive radioimaging method for detecting 
early atherosclerotic plaques. A novel polyiodinated cholesterol analog, cholesteryl1,3-
diiopanoate glyceryl ether (C21), radiolabeled with 1251, was incorporated into acetylated 
low density lipoprotein (AcLDL) which is considered as an atherosclerotic plaque 
seeking carrier. 1251-C21 was also prepared as a chylomicron-like emulsion. 125I-
C21/AcLDL or 125I-C21 emulsion was intravenously injected into apoE/LDL receptor 
(LDLR) double knockout mice that serve as an atherosclerosis animal model. The ex vivo 
images of radioactivity accumulated in the aortas 24 hours postinjection were compared 
to the atherosclerotic lesions revealed by histological studies. It was found that both 125I-
C21/ AcLDL and 1251-C21 emulsion resulted in accumulation of radioactivity at the site of 
early atherosclerotic lesions, and therefore may be useful for early detection of 
atherosclerosis. 
Treatments for atherosclerosis include general lipid-lowering strategies and 
approaches toward etiology. Among the multiple risk factors associated with 
atherosclerosis, familial hypercholesterolemia (FH) is the first genetic disorder 
recognized to cause severe premature atherosclerosis. Ultimate treatment for FH depends 
on gene therapy which can correct its WLR deficiency. The second part of this thesis 
focused on the development of a liver-targeting liposome vector for systemic gene 
therapy, with the objective of delivering mouse LDLR gene to the liver of the LDLR-
11 
knockout mouse, an animal model closely resembling human FH conditions. A peptide . 
from the circumsporozoite protein (CS) of malaria parasites was chosen as the liver-
targeting ligand. Cationic liposome/protamine/DNA (LPD) complex conjugated with the 
malaria peptide was prepared by different protocols and primarily investigated in vitro to 
transfect cultured cells with a reporter gene, either the chloramphenicol acetyltransferase 
(CAT) gene or the enhanced green fluorescent protein (EGFP) gene. Peptide-LPD 
complex showed higher CATIEGFP expression in HepG2 cells (human hepatoma cell 
line) than LPD itself, whereas no significant difference was observed in Hela cells 
(human cervical cancer cell line, control). However, these results were still preliminary 
and somewhat inconsistent. Further studies are needed. 
Finally, chapter 4 summarized other work using LDL as a potential targeting 
carrier for lipophilic antitumor drugs. A prodrug, dipalmitoyl-5-fluorodeoxyuridine 
( dpFUdR), was synthesized and incorporated into LDL. The antiproliferative effect of the 
resultant LDL-dpFUdR was investigated in human cervical cancer cells. 
Key words: atherosclerosis • apoEILDLR knockout mice • AcLDL • emulsion • 
cholesteryl 1,3-diiopanoate glyceryl ether (C21) • early detection • familial 
hypercholesterolemia (FH) • gene therapy • cationic liposome • LPD • malaria peptide • 
transfection • liver targeting • dipalmitoyl-5-fluorodeoxyuridine (dpFUdR) • LDL • 
anti proliferation 
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Chapter 1. Introduction and overview 
1.1 Atherosclerosis and the development of atherosclerotic lesions 
Atherosclerosis is a slowly developing, chronic degenerative disease of blood 
vessels (BV s ), which is characterized by the accumulation of lipids and fibrous elements 
in the wall of large and ytedium arteries. It is the primary cause of cardiovascular disease 
(CVD) including coronary heart disease and stroke. In economically privileged 
populations such as those of western societies, atherosclerosis is responsible for about 
50% of all deaths [Lusis, 2000]. 
It is now clear that atherogenesis is a long-term process developed in an 
inflammatory and hyperlipidemic environment. The atherosclerotic lesions are focal areas 
of intimal thickening formed through a very complex interaction between the vessel wall 
and blood components [Lusis, 2000; Glass and Witztum, 2001]. A primary initiating 
event is the deposit of lipid particles, low density lipoprotein (LDL), within the 
subendothelial matrix of the intima. When circulating LDL level is raised, both the 
transport of LDL into BVs and retention of LDL by BVs are increased. LDL particles 
diffuse passively through endothelial cell junctions and aggregate in the matrix of BV s, 
where they undergo certain modifications such as oxidation, lipolysis, and proteolysis. 
The accumulation of modified LDL stimulates the overlying endothelial cells to produce a 
1 
number of pro-inflammatory factors that can attract blood mononuclear cells and platelets. 
The monocytes then enter into the intima and subsequently differentiate to macrophages. 
The modified LDL can be rapidly taken up by macrophages via scavenger receptors, 
resulting in the formation of foam cells. The death of foam cells leaves behind a growing 
mass of extracellular. lipids and other cell debris. In parallel, smooth muscle cells (SMCs) 
abnormally proliferate and transmigrate from the media to intima. The intimal SMCs 
secrete extracellular matrix and give rise to a fibrous cap on the luminal aspect of the lipid 
core. The continuation of these processes leads to the formation of fibrolipid 
atherosclerotic plaques which may be rich in both connective tissue and lipid [Woolf, 
2001]. 
Typically, an atherosclerotic lesion, or plaque, consists of: (1) matrix-rich 
connective tissue including collagen, proteoglycans, and fibronectin elastic fibers; (2) 
crystalline cholesterol, cholesteryl esters, and phospholipids, which are derived largely 
from the plasma LDL; and (3) cells such as monocyte-derived macrophages, T-
lymphocytes, and SMCs [Libby, 1995]. Proportions of these components vary in different 
plaques, and have important impact on the natural history of the lesion. The local increase 
in volume of the plaque leads to narrowing of the arterial lumen (stenosis), and if this is 
sufficiently severe as to reduce the cross-sectional area of the lumen by 75% or more, or 
the diameter by 50% or more, the blood flow will be compromised and the patient is 
2 
likely to develop stable angina [Stary et al., 1995]. However, a plaque with a thin cap and 
a massive lipid/necrotic core is more likely to develop intimal injury, resulting in the 
rupture of the plaque. When it is disrupted, the underlying tissues are exposed to the 
blood, activating platelets and the clotting cascade. Large numbers of platelets then attach 
to the plaque surface and crosslink with fibrin to form a thrombus or blood clot. Although 
usually mildly stenotic, these so-called rupture-prone or vulnerable plaques are found to 
be more closely associated with life-threatening clinical situations than the severely 
stenotic lesions, such as unstable angina, acute myocardial infarction, stroke and sudden 
death due to the development of serious ventricular arrhythmias [Falk et al., 1995; Fayad 
and Fuster, 2001; Corti et al., 2002]. 
1.2 Lesion types and progressing phases of atherosclerosis 
In morphological terms, atherosclerosis can be defined as a systemic disorder 
involving the intima of large elastic and muscular arteries such as the aorta, the epicardial 
coronary, femoral and carotid arteries [Corti et al., 2002]. In humans, early 
·, 
atherosclerotic lesions can usually be found in the aorta in the first decade of life, the 
coronary arteries in the second decade, and the cerebral arteries in the third or fourth 
decades. Because of differences in blood flow dynamics, there are preferred sites of 
3 
lesion formation within the arteries such as regions of arterial branching or curvature 
where flow is turbulent [Gimbrone, 1999]. 
According to the criteria of the American Heart Association Committee on 
Vascular Lesions, atherosclerotic lesion can be categorized to six types (Table 1.1) [Stary 
et al., 1994; Stary et al., 1995]. 
Table 1.1. Pathological classification of human atherosclerotic lesions 
Lesion types Main histology Earliest Clinical 
onset correlation 
Type I lesion Isolated macrophage foam From (initial) cells first Clinically 
decade silent Type II lesion Mainly intracellular lipid (early 
(fatty steak) accumulation lesions) 
Type ill lesion Type II changes & small 
(intermediate) extracellular lipids From 
third 
Type IV lesion Fibrolipid plaques with decade 
(atheroma) confluent extracellular Clinically 
lipid pools silent or 
overt 
Type V lesion Lipid core & fibrotic layer, (advanced 
(fibroatheroma) or multiple lipid cores & lesions or 
fibrotic layers (Va), or From raised 
mainly calcific (Vb ), or forth lesions) 
mainly fibrotic (V c) decade 
Type VI lesion Surface defect, hematoma-
(complicated) hemorrhage, thrombus 
4 
Based on gross pathological and clinical findings, the progression of coronary 
atherosclerotic disease can also be classified into five phases [Fuster et al., 1992; Fuster, 
1994]. 
Phase 1 Phase 2 
No Symptoms 
Phase4 
II 
Acute Syndromes 
Myocardial infmdion 
Unstable angina . 
IM:hemic sudden death 
lf ~ \ ____ ....... 
Phase3 
PhaeeS 
Angina 
Pectoris 
Figure 1.1. Phases and lesion morphology of the progression of coronary atherosclerosis 
(Copied from Fayad and Fuster, 2001 with permission) 
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As shown schematically in Figure 1.1, phase 1 is represented by a small plaque that '• 
is categorized as type I to III lesions. It is present in most people under the age of 30 
years and usually progresses very slowly. Phase 2 is characterized by the presence of 
plaques that, although not necessarily very.stenotic, have a high lipid content that is very 
prone to rupture (types IV and Va lesions). Disruption of phase 2 plaques may lead to the 
formation of either mural or occlusive thrombus, representing acute phase 3 or phase 4, 
respectively. Phase 3, consisting of type VI lesions, could possibly progress into stenosis, 
resulting in angina. Phase 4 may be associated with acute coronary syndromes and type 
VI lesions of phase 4 can also evolve into a fibrotic phase (phase 5) characterized by 
more stenotic plaques that may proceed to occlusive lesions (types Vb and Vc lesions). 
This process of occlusion from late stenotic plaques tends to be silent because the 
preceding severe stenosis and ischemia enhance protective collateral circulation [Fuster et 
al., 1992; Fayad and Fuster, 2001]. 
1.3 Etiology of atherosclerosis and familial hypercholesterolemia (FH) 
Epidemiological studies over the past 50 years have revealed numerous risk factors 
for atherosclerosis. These can be grouped into factors with a significant genetic 
component, and those that are largely environmental [Lusis, 2000; Glass and Witztum, 
2001]. As listed in Table 1.2, the common forms ofCVD result from the combination of 
6 
an unhealthy environment, genetic susceptibility and our increased lifespan. Among the 
many risk factors, there is a complex interaction between some factors; for example, the 
effects of hypertension on CVD are considerably amplified if cholesterol levels are high. 
Moreover, the relatively elevated atherogenic lipoproteins appear to be of primary 
importance, as raised level of plasma cholesterol is a prerequisite for most forms of the 
disease. Even in the absence of other known risk factors, an elevated cholesterol level is 
probably sufficient to drive the development of atherosclerosis in humans and 
experimental animals [Glass and Witztum, 2001]. 
Plasma cholesterol is carried by several lipoprotein particles that perform the 
complex physiologic tasks of transporting dietary and endogenously produced lipids 
[Packard and Shepherd, 2001]. Chylomicrons provide the primary means of transporting 
dietary lipids, while very low density lipoprotein (VLDL), LDL, and high density 
lipoprotein (HDL) function to transport endogenous lipids. In humans, LDL is the main 
vehicle for the delivery of cholesterol to peripheral tissues, and it is taken up by cells via 
LDL receptors (LDLRs) that recognize the apolipoprotein (apo) B-100 on its surface. 
The circulating level of LDL is determined in large part by the rate of liver uptake 
through the hepatic LDLR pathway, as evidenced by the fact that lack of functional 
LDLR is responsible for the massive accumulation of LDL-bound cholesterol in patients 
with homozygous familial hypercholesterolemia (FH) [Brown and Goldstein, 1986]. 
7 
Table 1.2. Risk factors for the development of atherosclerosis 
Factors with a strong genetic component 
Elevated levels ofLDL and VLDL 
Low levels ofHDL 
Elevated levels of lipoprotein( a) 
Hypertension 
Diabetes mellitus 
Obesity 
Gender (male) 
Family history 
Elevated levels of homocysteine 
Elevated levels of hemostatic factors, e.g. fibrogen 
Metabolic syndrome, such as insulin resistance 
Systemic inflammation 
Depression and other behavioural traits 
Environmental factors 
High fat diet 
Smoking 
Lack of exercise 
Infectious agents 
Low antioxidant levels 
FH is the first genetic disorder recognized to cause myocardial infarction, a fatal 
clinical consequence of atherosclerosis [Goldstein et al., 2001]. To this day, it remains 
the most typical example used to illustrate relations between high plasma cholesterol 
levels and coronary atherosclerosis [Stehbens, 2001]. 
FH results from a mutation in the gene specifying LDLR, one of the most 
extensively studied receptors in genetics. Five classes of gene mutations at the LDLR · 
locus have been identified and each class can be subdivided into multiple alleles through 
8 
molecular characterization. More than 420 different mutant alleles have been found in 
different FH patients. Many of these mutations disrupt receptor function in meaningful 
ways [Goldstein et al., 2001]. The clinical characterizations of FH include a lifelong 
elevation of LDL concentration, deposition of LDL-derived cholesterol in tendons and 
skin (xanthomas), as well as in arteries, and premature atherosclerosis. Inherited as an 
autosomal dominant trait, FH homozygotes (two mutant alleles at the LDLR locus, either 
identical or different) are more severely affected than are heterozygotes (one normal 
allele and one mutant allele). Heterozygotes occur in the population at a frequency of 
about 1 in 500, placing FH among the most common monogenic diseases in humans. 
Cholesterol levels in heterozygotes elevate twofold from birth (350 to 550 mg/dl) and 
coronary atherosclerosis generally develops after age 30. Homozygotes, on the other 
hand, number 1 in 1 million persons and have severe hypercholesterolemia (650 to 1000 
mg/dl). Coronary heart disease begins in childhood and frequently causes death from 
myocardial infarction before age 20. 
In addition to the finding of a raised level of LDL cholesterol from childhood, 
diagnosis ofFH also requires either the demonstration of a decrease in LDLR activity, the 
documentation of mutation in the LDLR gene, or the presence of other clinical features 
such as tendon xanthomas, premature atherosclerosis, and autosomal dominant 
transmission [Goldstein et al., 2001]. 
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1.4 Imaging modalities for the detection of atherosclerotic lesions 
It is known that early identification of patients at high risk for development of CVD 
and subsequent intervention with lifestyle changes and, where necessary, drug therapy 
would have substantial benefit for reducing cardiovascular morbidity and mortality [Corti 
et al., 2002]. Besides evaluation of clinical risk factors, which are not adequate and 
sometimes not timely, directly imaging atherosclerosis at its early stage is a promising 
approach for identifying patients who are at increased risk for cardiovascular events. It 
may also provide a tool for better understanding the plaque biology, monitering a 
patient's response to therapy, and testing new therapeutic approaches. Currently, a 
number of invasive and noninvasive methods are used to study atherosclerosis, and most 
of them identify luminal diameter or stenosis, wall thickness, and plaque volume. 
Angiography, a traditional imaging technique, remains the "gold standard" for 
evaluating luminal narrowing or stenosis resulting from the formation of atherosclerotic 
plaque. It may also reveal advanced lesions, plaque disruption, luminal thrombosis, and 
calcification [Fayad and Fuster, 2001]. However, angiography can only provide limited 
information about histopathological features of individual plaques, which is, as 
summarized in the section 1.1, more valuable for prediction of lesion progression. As an 
invasive method, angiography is associated with significant risk. 
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Angioscopy uses visible light to image the plaque surface. As it can reveal surface 
features of the plaque, intravascular angioscopy is able to detect thrombus formation and 
lipid accumulation, although it has not gained significant clinical use. It is also invasive 
and cannot evaluate deeper plaque components [Thieme et al., 1996]. 
Catheter-based ultrasound or intravascular US (IVUS) is a new approach to arterial 
vascular wall imaging with high-resolution [York and Fitzgerald, 1998]. This invasive 
modality directly provides cross-sectional tomographic images of the vessel and lesion 
area. Diagnostic applications of IVUS include detection of angiographically 
unrecognized disease, detection of intermediate lesions (40-75% stenosis) and 
calcification, and certain risk estimation for intervention of atherosclerosis. The limitation 
of IVUS is its low sensitivity in detection of thrombus and lipid-rich lesions. 
Some other new invasive techniques, namely, optical coherence tomography (OCT), 
Raman spectroscopy and near-infrared spectroscopy, are undergone exploration and have 
shown promise in characterizing lesion compositions with high resolution [Pasterkamp. et 
al., 2000]. Noninvasive methods, such as B-mode ultrasound (US), computed 
tomography (CT), magnetic resonance (MR) imaging and nuclear scintigraphy, are 
obviously safer and easier for practice than the above invasive techniques. 
Ultrasound and Doppler flow studies have been used extensively to measure 
severity of stenosis in peripheral arteries. It is also the dominant clinical method for 
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evaluation of carotid artery disease including carotic atherosclerosis. Measurements of 
carotid and aortic wall thickness as well as qualitative and quantitative analysis of plaque 
such as calcification, lipid accumulation, and thrombus can also be determined by surface 
and transesophageal US, and each of these features is correlated with the evaluated risk of 
CVD [Gronholdt, 1999; Fazio et al., 1993]. However, this usage has not yet been 
standardized and integrated into clinical practice, and requires further study. 
CT is a kind of X-ray-based technique, which demonstrates high sensitivity to 
calcification. It is therefore capable of noninvasively detecting human coronary artery 
calcification in the clinic, which in general represents the burden degree of atherosclerotic 
plaque. However, CT has limited capability to .characterize soft tissue such as lipids, a 
feature associated with plaque vulnerability. With the development of multidetector 
scanners, CT technology continues to improve and significant potential still exists for the 
early identification of patients at increased risk [Callister et al., 1999]. 
High-resolution MR imaging is the leading imaging modality for characterization of 
atherosclerotic lesions on the basis of biophysical and biochemical information. It can 
theoretically distinguish the plaque components, including lipid, fibrous element, calcified 
region and thrombus, as well as the plaque disruption. Some promising results have been 
obtained in animal models or human subjects [Skinner et al., 1995; Toussaint et al., 1996}. 
However, MR still lacks sufficient resolution (currently 0.4 mm) for accurately measuring 
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cap thickness and imaging lesions within coronary arteries due to their small size as well 
as cardiac and respiratory motion [Fayad et al., 2000]. 
1.5 Nuclear scintigraphy imaging techniques 
Nuclear scintigraphy images arise from injected radioactive tracers which 
subsequently emit radiation from within body organs. It is based on the specific binding 
of radioactively labeled molecules to the target tissue, in this case the atherosclerotic 
lesion. Because the detection method evaluated in the work of this thesis is related to 
nuclear tracer imaging, this approach will be discussed in some detail in this section. 
An ideal radiotracer for visualizing the vulnerable plaque should meet the following 
criteria [Vallabhajosula and Fuster, 1997]: 
. (1) it must be specific for lipid core, macrophage density or thrombus; 
(2) it must be able to detect lesions in all atherosclerotic artery types that are related 
to clinical symptoms; 
(3) it must be able to assess progression-regression of atherosclerosis; 
( 4) it must be able to predict clinically significant events; 
(5) it must be able to provide prognostic indicators in population studies; 
( 6) it must have a kit formulation for instant preparation, high specificity and 
sensitivity, fast blood clearance and high lesion to blood ratios. 
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There are no single radiotracers that meet all these conditions. Attempts to image 
areas of active atherosclerosis started with the labeling of one of the major but nonspecific 
components of plaques, LDL or Oxidized LDL (OxLDL}, and have progressed to the use 
of smaller antibody fragments and peptides against specific components of the 
atherosclerotic plaque or thrombus, such as macrophages, smooth muscle cells, 
endothelial adhesion molecules and platelets [Narula et al., 1999]. These tracers were 
radiolabeled with radioiodine, 99m.rc, 111In, or 125In, and showed significant uptake in 
experimental atherosclerotic lesions. Table 1.3 lists the potential targets for vulnerable 
plaque imaging [Cerqueira, 1999]. However, the limited clinical trials could not 
demonstrate their utility because of the slow clearance of radiotracers from the circulation 
and poor target/background ratios [Vallabhajosula and Fuster, 1997; McConnell, 2000]. 
In addition, relatively low spatial resolution and high blood-pool signal have limited the 
clinical application of nuclear techniques to date. 
A common drawback of all radiolabeled native products, including LDLs, peptides, 
and immunoglobulins, is that once these radiotracers are taken up by the target tissues, 
they will be quickly degraded within the lysosomal compartment inside the cell and then 
be excreted, which· compromises the selectivity of these targeting tracers for long-term 
monitoring. Attempts to overcome this problem have led researchers to study agents that 
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would remain in the cell once internalized. To this end, cholesteryl 1,3-diiopanoate 
glyceryl ether (C21), a novel cholesterol analogue, was first synthesized by our lab. 
Table 1.3. Potential targets for imaging vulnerable atherosclerotic plaques 
LDL cholesterol 
Proliferating smooth muscle cells 
Up-regulated receptors 
Tyrosine kinase activity: Endothelin-1derivative, 9~C-ZK167054* 
G-protein signaling related: Purine analog, 99rotrC-Ap4A ** 
Surface antigenic moieties: 111In-Z2D3t 
Macrophage infiltration in atherosclerotic plaques 
Large lipid cores in atherosclerotic lesions: 1231-SP4~ 
[* Dinkelborg et al., 1998; ** Elmaleh et al., 1998; t Narula et al., 1995; ~ Hardoff 
et al., 1993] 
As shown in Figure 1.2, the C21 molecule contains an ether bond, which is resistant 
to endocellular hydrolysis. Moreover, each C21 molecule bears six iodines, providing it a 
great potential for a high specific radioactivity after these iodines are exchanged by their 
radioactive counterparts, such as 1251 and 1231. This lipophilic compound has been 
incorporated into acetylated LDL (AcLDL) and preliminarily examined in a rabbit model 
for the detection of atheroeclerotic lesions ex vivo [Xiao2 et al., 1999]. 
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Figure 1.2. The structure of cholesteryl1,3-diiopanoate glyceryl ether (C21) 
In the current project, apoE and LDLR double knockout rmce, which are 
homozygous for targeted disruptions of the genes for both apoE and the LDLR [ apoE( -/-); 
LDLR(-/-)], were chosen as the animal model to evaluate the potential of the above 
radiotracer, 1251 labeled C21 (1251-C21), since they can develop atherosclerotic lesions 
closely-resembling those of humans [Smith and Breslow, 1997]. AcLDL was used as a 
selective carrier for 125I-C21 because (1) the hydrophobic core of AcLDL particle provides 
a large space for retaining such lipophilic compounds; (2) it is known that macrophages in 
atherosclerotic plaques express a scavenger receptor for modified LDL such as OxLDL 
and AcLDL. Therefore it is rational to use the differential uptake of AcLDL as an 
approach to deliver radioimaging probes for the detection of early atherosclerotic lesions. 
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In addition, AcLDL had been proven to have a faster blood clearance than native LDL 
[Van Berkel et al., 1991], which would facilitate its utility in nuclear imaging by 
enhancing the tissue-background ratio of radioactivity. On the other hand, 125I-C2I was 
also formulated into a lipid emulsion which can be considered as an artificial lipoprotein 
particle imitating chylomicron remnant, a known atherogenic factor. Although the 
chylomicron remnant is physiologically metabolized mainly in the liver, it can also be 
internalized by extrahepatic tissues including macrophages in the artery wall [Terpstra, 
2000]. We therefore expected the chylomicron-like emulsion formulation to deliver 125I-
C2I to early atherosclerotic lesions. 
1.6 Treatment strategies for atherosclerosis and gene therapy for FH 
As atherosclerosis is a chronic disease requiring prevention over the course of a 
lifetime, modification of life-style is the first basic step. Preventive measures including 
regular exercising, quitting smoking, and replacing dietary saturated fatty acids· with 
unsaturated fats, have proven merits. In addition to the control of diseases that may 
contribute to atherosclerosis, such as hypertension and diabetes, medical interventions that 
markedly alter the balance of atherogenic vs antiatherogenic lipoproteins are associated 
with inhibition of lesion progression. It has been shown that aggressively lowering LDL 
cholesterol reduces cardiovascular morbidity and mortality, and prevents the development 
17 
of atherosclerosis [Chait and Heinecke, 1999]. Statins, the first-line cholesterol-lowering 
drugs, are capable of stabilizing atherosclerotic plaques independent of their 
hypolipidemic effect [Brown et al., 1993; Shah, 1997]. A novel cholesterol transport 
inhibitor, ezetimibe, can selectively inhibit the uptake of cholesterol from the intestinal 
lumen, and offers a new therapeutic option for decreasing LDL cholesterol [Gagne et al., 
2002]. Some other medications including angiotensin-converting enzyme (ACE) 
inhibitors may also, at least in part, decrease the plaque vulnerability [Pitt, 2000]. 
Antioxidants have been recommended as well in order to reduce the risk, although the 
therapeutic benefits of inhibition of oxidative processes are still in clinical trial stages. 
For acute coronary syndromes, besides mechanical interventions, there are several 
pharmacological strategies that have been developed to dissolve preformed thrombi and 
inhibit thrombogenesis. These agents can be subdivided by their mechanisms of action 
into three categeries: fibrinolytics, inhibitors of the intrinsic coagulation cascade (e.g. 
heparins, antithrombins), and antiplatelet agents [Corti et al., 2002]. 
Gene engineering technology using overexpression or knockout genes of interest 
has provided genetically manipulated mice models for the study of underlying molecular 
mechanisms of atherosclerosis and thus accelerated the pace of discovering novel 
therapeutic agents. Small molecule-based approaches targeting enzymes or transcription 
factors involved in atherogenic process have been found to have great potential [Glass and. 
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Witztum, 2001]. Moreover, gene therapy represents an ultimate means to correct some 
genetic disorders leading to atherosclerosis, in particular, FH. 
Current therapy for FH is a combination of a stringent diet to decrease cholesterol 
intake and pharmacological agents to increase the removal of cholesterol, as well as 
plasma exchange or LDL apheresis in some severe cases [Goldstein et al., 2001]. 
However, some patients cannot achieve optimal LDL cholesterol levels with the above 
approaches. The majority of these patients are homozygous FH. Although LDLRs are 
expressed ubiquitously, the hepatic LDLR has the greatest quantitative effect in 
controlling plasma LDL levels. Importantly, a limited number of patients with 
homozygous FH have undergone liver transplantation and have experienced substantial 
reduction in LDL cholesterol levels [Goldstein et al., 2001]. Success of the liver 
transplantation suggests that gene therapy targeted toward the liver would likely be an 
effective strategy for the treatment of FH. 
Gene therapy can be defined as the transfer of genetic material to specific target 
cells/tissues of a patient where its expression produces a therapeutic effect, ultimately 
preventing or altering a particular disease state. Carriers or delivery vehicles for 
therapeutic genetic material are called vectors, and there are viral and non-viral vectors 
being studied now [Jain, 1998]. Introduction of functional LDLR genes in the liver 
through an ex vivo gene therapy approach has been conducted in five FH homozygous 
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patients with coronary artery disease [Grossman et al., 1995]. In this clinical trial, liver 
cells were transfected ex vivo with a retrovirus expressing the LDLR and theQ, , , , 
reintroduced into the liver via the portal vein 3 days after the initial surgery. All patients 
were found to have tolerated the procedure without significant complications. Transgene 
expression was detected in a limited number of hepatocytes and liver tissue harvested 4 
months after gene transfer from all five patients. Significant and prolonged reduction in 
LDL cholesterol was demonstrated in three of the five patients. However, the marginal 
effectiveness and the complexity of the process preclude more widespread use of this 
method of the treatment. The development of in vivo gene therapies based on 
recombinant adenoviruses encoding LDLR or VLDL receptor may facilitate a broader 
application of these approaches. Although encouraging results have been observed in 
several animal experiments [Kozarsky et al., 1994; Ishibashi et al., 1993; Kozarsky et al., 
1996], immunogenicity and higher toxicity of viral vectors so far make them less 
attractive than non-viral vectors. 
Cationic liposomes are a promising group of non-viral vectors for gene transfer, 
which exhibited adequate features for in vivo use. In the last decade, extensive effort has 
been devoted to the development and optimization of this strategy [Lee and Huang, 1997]. 
Numerous novel preparations of cationic liposomes have been formulated and several 
clinical trials using cationic liposome-DNA complexes (lipoplexes) have been performed 
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for the treatment of cystic fibrosis and cancer [Nabel et al., 1993; Caplen et al., 1995]. It 
has been shown that a LPD (cationic liposome/polycationic peptide such as 
protamine/DNA) complex has great potential for intravenous gene delivery [Li et al., 
1998]. However, transgene expression is widely distributed throughout the body of the 
living host following systemic administration. In our project, a liver targeting LPD 
complex was developed using a malaria peptide as the hepatocyte--specific ligand. The 
final objective of this project is to correct LDLR deficiency in LDLR knockout mice, an 
animal model of human FH, using the liver-specific LPD vector carrying mouse LDLR 
gene. However, the work conducted in the thesis, as summarized in chapter 3, was 
focused on in vitro studies of the malaria peptide--LPD formulations. 
The other work, using LDL as a potential targeting carrier for lipophilic antitumor 
drugs, was also summarized as an appendix in this thesis. Because its content is 
somewhat far from the major project, it will be briefly introduced and discussed in chapter 
4. 
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Chapter 2. Ex vivo evaluation of a novel polyiodinated 
compound for early detection of atherosclerosis* 
2.1 Introduction 
CVD remains the leading cause of morbidity and mortality in Western countries 
[Lusis, 2000; Glass and Witztum, 2001]. Perhaps the major obstacles to significantly 
reducing the problems associated with the disease are the multifactorial nature of the 
disease and its slow and insidious development. While the management of CVD includes 
both. prevention and treatment, strategies aimed at prevention are known to be more cost 
effective and beneficial than those focused on treatment of the disease at more advanced 
stages [Farquhar, 1995]. Successful prevention, however, depends on early assessment of 
individuals at great risk. Angiography, although the "gold standard" for diagnosis of 
atherosclerosis, is invasive, and it detects only advanced lesions since stenosis of the 
blood vessel is required for the technology. There are several noninvasive methods 
available clinically such as X rays, ultrasound, CT, MR., and nuclear scintigraphy, but 
they all have unique advantages and limitations [McConnell, 2000]. There remains a 
need for an effective and noninvasive diagnostic method for the early detection of 
atherosclerosis. 
* Published in part in Radiation Research (Vol.l60, No.4, pp460-466, 2003), Kang, Z., Scott, T. M., 
Wesolowski, C., Feng, L., Wang, J., Wang, L. and Liu, H. 
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Atherosclerosis is a long-term process developed in a complex inflammatory and 
hyperlipidemic environment [Lusis, 2000; Glass and Witztum, 2001]. It involves 
monocyte-macrophages in the arterial intima and the accumulation of lipids from LDL to 
form cholesteryl esters (CEs) enriched foam cells. It is known that macrophages express 
a sca,venger receptor for modified LDL such as OxLDL and AcLDL [Voyta et al., 1984; 
Brown et al., 1980]. It has been found that accumulation of LDL in the arterial wall is 
increased in areas involved in lesions [Roberts et al., 1983; Poledne et al., 1986]. Use of 
this differential uptake of LDL as an approach to deliver radioimaging probes for the 
early detection of atherosclerotic lesions seems to be a valid rationale considering the 
critical role played by LDL in the early stage of atherogenesis. Furthermore, an imaging 
modality would theoretically permit the visualization of the lesion itself. 
Although strategies of employing radiolabeled cholesterol for the detection of 
atherosclerosis have been investigated previously, the results suggested that the 
radiolabeled probes suffered from instability due to rapid enzymatic digestion in 
macrophages [DeGalan et al., 1988]. To overcome this limitation, in this study, we used a 
radioiodinated cholesterol analogue, 125I-C2I, which was first synthesized in our lab [Xiao 
et al., 2003], as a radioimaging agent. 125I-C2I was incorporated into AcLDL, a lesion-
specific carrier, or prepared as a phospholipid emulsion formulation. The resultant 125I-
C2I/AcLDL and 125I-C2I emulsion were examined for their potential to be used for the 
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detection of early atherosclerotic lesions in homozygous apoEILDL receptor (LDLR) 
knockout mice. The double targeted mutant mice are associated with spontaneous 
elevations in plasma cholesterol level; when fed with normal chow diet, they develop 
atherosclerotic lesions closely-resembling those of humans [Ishibashi et al., 1994]. They 
have become the most frequently used animal models in recent atherosclerosis studies 
[Smith and Breslow, 1997; Dansky et al., 1999]. The rationale for studying 125I-C2I 
emulsion, in addition to 125I-C2I/ AcLDL, was because lipid emulsion has been suggested 
to simulate chylomicron metabolism and thus can be internalized by macrophages 
including those involved in atherosclerotic lesions [Redgrave, 2001]. 
2.2 Materials and methods 
2.2.1 Materials 
Thin layer chromatography (TCL) was carried out on silica gel-60, F-254 
polyethylene-backed plates (Fisher Scientific, Ottawa, ON, Canada). Sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed on a Mini-
PROTEA~ II Electrophoresis Cell (Bio-Rad Laboratories Ltd., Mississauga, ON, 
Canada). Sonication was executed with Virsonic Cell Disrupter Model 16~850 (VirTis 
Company Inc., Gardiner, NY, USA). Sephadex® G-25 (medium, from Amersham 
Biosciences, Quebec, Canada) gel filtration was carried out using a Poly-Pre® 
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chromatography column (Bio-Rad). Radioactivity was measured using an LKB-Wallac 
1277 GAMMAMASTER automatic gamma counter (Wallac Oy, Turku, Finland). 
Carrier free Na1251 was purchased from NEN Life Science Products, Inc. (Guelph, 
ON, Canada). SDS-PAGE molecular weight standards and bovine serum albumin (BSA) 
were obtained from Bio-Rad. All other chemicals were from Sigma-Aldrich Canada Ltd. 
(Oakville, ON, Canada) unless otherwise indicated. 
2.2.2 Preparation of 125I-C21 
C21 was synthesized according to a method developed previously in this lab [Xiao 
et al., 2003] and radiolabeled with 1251 via an iodine exchange reaction in a pivalic acid 
melt [Weichert et al., 1986]. The 1251-labeled C21 was purified by chromatography. The 
radiochemical purity of 1251-C21 was determined by TLC using chloroform as the mobile 
phase in conjunction with AR-2000 Imaging Scanner (BIOSCAN, Inc., Washington, DC, 
USA). 
2.2.3 Preparation of AcLDL 
LDL was isolated from fresh human plasma obtained from healthy volunteers by 
sequential ultracentrifugation [Schumaker and Puppione, 1986] using a Beckman L8~M 
ultracentrifuge and 60/75 Ti rotors. All LDL preparations were dialysed at 4°C overnight 
against a buffer containing 0.3 mM EDTA, 150 mM NaCl and 50 mM Tris (pH 7.4). 
AcLDL was prepared by adding excess acetate anhydride and sodium acetate to the LDL 
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preparation obtained above [Basu et al., 1976], then subjected to 1% agarose gel· 
electrophoresis. The protein integrity of AcLDL was examined using 6-20% gradient 
SDS-PAGE [Laemmli, 1970]. Protein concentrations were determined by the method of 
Bradford [Bradford, 1976] using a Bio-Rad protein assay kit with BSA as the standard. 
2.2.4 Preparation of 125I-C2I emulsion 
1251 -C21 emulsion was prepared according to a previously published method [Xiao 1 
et al., 1999]. In brief, a mixture of 12 mg L-a-phosphatidylcholine (PC), 8 mg DL-a-
phosphatidylethanolamine dipalmitoyl (DPPE), 20 mg seal oil (Terra Nova Fishery, 
Newfoundland, Canada) and 10 mg 1251-C21 in chloroform were dried under a nitrogen 
stream and re-suspended in I 0 m1 of saline. The suspension was then sonicated for 2 h at 
0°C and centrifuged at 40,000 rpm for 7 hat 4°C. The emulsion that floated to the top of 
the centrifuge tube was collected and the radioactivity was determined. Emulsions were 
used for experiments within 5 days of preparation. 
2.2.5 Preparation of 12~-C2I/ AcLDL 
125I-C21/AcLDL was prepared by incubating 125I-C21 emulsion with AcLDL 
obtained as described above at 37°C for 8 h after which 125I-C21/AcLDL was separated by 
ultracentrifugation. 1251-C21/AcLDL was then characterized by gel filtration [Xiao1 et al., 
1999; Xiao2 et al., 1999]. Briefly, 500 fll 125I-C21/AcLDL preparation was loaded onto a 
Sephadex® G-25 chromatography column and eluted with phosphate buffered saline (pH 
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7.4). Fractions of 500 fll were collected, and radioactivity and protein content of each 
fraction were determined by gamma counter and the Bradford method, respectively. 
Results were then plotted. 
2.2.6 Animal model and protocol 
ApoEILDLR knockout mice (B6;129-ApoetmlUncLd.JI"'JHer mice, female, age 7-8 
weeks, average weight 22 g) were purchased from the Jackson Laboratory (Bar Harbor, 
MA, USA) and maintained on a normal chow diet during the whole study. They were 
randomly divided into two test groups: 1251-C21/AcLDL group (n = 10) and 125I-C21 
emulsion group (n = 6), and 3 extra mice were used for the examination of atherosclerotic 
lesions. C57 mice (n = 8, female, age fr-7 weeks, average weight 20 g) were kindly 
provided by Dr. C. Kovacs (Faculty of Medicine, Memorial University of Newfoundland) 
and used as a control. The animal study was reviewed and approved by the University's 
animal care committee. Blood samples were obtained from the retroorbital plexus every 
4 weeks when the mice were anesthetized with inhalation of d.iethyl ether (BDH Inc., 
Toronto, ON, Canada), and plasma cholesterol levels were determined enzymatically with 
an assay kit from Sigma. After 8 weeks of feeding, early stage atherosclerotic lesions 
were found in the aortas of three apoEILDLR knockout mice that were examined (age i5-
16 weeks). Two weeks later, each animal (age 18-20 weeks) was anesthetized with 
inhalation of d.iethyl ether and then injected with 125I-C21/AcLDL (1.85 MBq/kg) or 1251-
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C2I emulsion (3.33 MBq/kg) via the tail vein. The mice were sacrificed humanely 241i 
postinjection by over exposure to diethyl ether, and Zamboni's fixative (2% 
paraformaldehyde in O.lM phosphate buffer with 15% v/v saturated picric acid, pH 7.2) 
was perfused through the heart. Various organs including liver, kidney, adrenal gland, 
spleen, lung, aorta, blood and thyroid were collected, and radioactivity associated with 
each sample was determined using a gamma counter. It should be noted that the 
radioactivity for the aorta was based on the weight of the entire aorta and that the specific 
radioactivity for just the plaque was not assessed. 
2.2. 7 Ex vivo aorta imaging 
The aorta samples collected were further cleaned by removing the connective 
tissues and were fixed in Zamboni' s fixative overnight. Then the aortas were stained with 
' 
Sudan IV dye, and subsequently exposed to a Cyclone™ Phosphor Storage S~een 
(Packard Instrument Company, Inc., Meriden, CT, USA) at room temperature for 6-8 h 
following which the results were read by a Cyclone™ scanner. 
2.2.8 Data analysis 
Statistical analysis of the data was performed using a nonpaired Student's t test. A 
p value of 0.05 or less was considered to indicate a significant difference between the sets 
of data. 
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2.3 Results 
A novel compound, C21, was synthesized and labeled with 1251. TLC scanning of 
the resultant product showed a radioactive peak at Rr= 0.47 which was identical to that of 
C21 (Figure 2.1 ). The radiochemical purity was found to be about 95%. 125I-C21 
emulsion was then prepared and its specific activity was 2.55 MBq/ml. Incubation of the 
125I-C21 emulsion with AcLDL resulted in 125I-C21/AcLDL (200 1251-C21 molecules per 
AcLDL particle). As shown in Figure 2.2, Sephadex® G-25 gel filtration of 125I-
C21/AcLDL revealed that the profiles of radioactivity and protein absorbance were 
overlapped, indicating that 125I-C21 was associated with AcLDL. The specific 
radioactivity of 125I-C21/AcLDL was 0.925 MBq/ml. Agarose gel electrophoresis results 
demonstrated that 125I-C21/AcLDL had a greater mobility than LDL (Figure 2.3), which is 
due to the increased negative charge on the surface of AcLDL [Hu et al., 2000]. When 
examined by 6-20% gradient SDS-PAGE analysis, the 125I-C21/ AcLDL preparation 
exhibited a single apoB-100 band identical to that ofLDL or AcLDL control. No other 
protein bands were found, suggesting that there was no protein degradation (Figure 2.4). 
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Figure 2.1. Chemical purity and radiochemical purity of 1251-C21. (A) TLC 
result of 1251 labeled C21 under a mobile phase of 100% chloroform (Rf = 
0.47). (B) Radioactivity scanning ofTLC plate A along the 1251-C21 running 
direction showed the Rf value of the radioactivity peak was also 0.47, 
indicating that it was from the 1251-C21 spot. The horizontal axis represents 
the height of the plate A and the vertical axis indicates the radioactivity 
counts per minute. 
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Figure 2.2. Chromatograms of gel filtration (Sephadex® G-25) of 1251-
C21/ AcLDL preparation with respect to its radioactivity and protein 
absorbance at 595 nm (the Bradford method). 
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Figure 2.3. Agarose gel (1 %) eletrophorosis of LDL and 1251-C21/AcLDL. 
The Coomassie blue-prestained samples were run in TBE buffer (89 mM 
Tris borate, 2 mM EDTA, pH 8.6) at 100 V for 30 min. 1251-C21/AcLDL 
showed a faster mobility than LDL due to the increased negative charge on 
the surface AcLDL. 
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Figure 2.4. Gradient SDS-PAGE (6-20%) analysis of 1251-C21/AcLDL, 
AcLDL and LDL. Approximately 1-3 Jlg protein was loaded for each 
sample and electrophoresed at 200 V for 45 min. The separating gel was 
stained with Coomassie blue R250. The positions of a broad range of 
molecular weight standard (x kDa) are shown with arrow marks. 
33 
Both apoEILDLR knockout and control C57 mice were maintained on a normal 
chow diet. Plasma cholesterol levels were determined and the results after 8 weeks of 
feeding are presented in Table 2.1. In comparison to the control group (2.95 mmol/L), the 
apoEILDLR knockout mice demonstrated a 5 times higher cholesterol level (15.14 
mmol/L ), suggesting that atherosclerotic lesions were likely to have developed. Three 
mice were subsequently dissected and the aortas were examined under a microscope. It 
was confirmed that early stage atherosclerotic lesions had developed. Two weeks later, 
125I-C2I/AcLDL or 125I-C21 emulsion was administered intravenously to both 
apoEILDLR knockout mice (at age of 18--20 weeks) and control mice at 1.85 MBq/kg for 
125I-C2I/AcLDL and 3.33 MBq/k:g for 125I-C21 emulsion. Figures 2.5 and 2.6 illustrated 
the radioactivity found in various tissues 24 h postinjection of 125I-C2I/ AcLDL and 125I-
C21 emulsion, respectively. For both apoE/LDLR knockout mice and control mice, it was 
found that 125I-C2I/AcLDL resulted in the highest accumulation in the adrenal gland 
followed by the liver, while 125I-C21 emulsion produced the highest level of radioactivity 
in the liver followed by the spleen. It was also found that, after the administration of 125I-
C2I/AcLDL or 125I-C21 emulsion, there was no statistical difference in the radioactivitiy 
of the liver, spleen, kidney, lung, adrenal gland and fat tissue between the apoEILDLR 
knockout mice and control. However, the accumulation of radioactivity in the aorta and 
blood of the apoEILDLR knockout mice was significantly higher than that in the control 
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group. The radioactivity in the aortas of the apoEILDLR knockout mice was about 11 
times higher than that of the control mice after administration of 125I-C21/AcLDL 
(1.3xl04 vs.l.lxl03 cpmlg tissue), and 4.5 times higher after administration of 125I-C21 
emulsion (2.4xl05 vs. 5.3xl04 cpmlg tissue). Table 2.2 summarized the radioactivity 
distribution expressed as percent of injected dose per gram of organ. It can be seen that 
125I-C21/AcLDL resulted in a faster clearance from the body than 1251-C21 emulsion 24 h 
after i. v. injection. Another tissue containing high concentration of radioactivity in both 
groups was found to be thyroid as expected, 3.6xt06 or 4.1xt05 cpmlg tissue following 
administration of 125I-C21 emulsion or 1251-C21/AcLDL, respectively. As is common for 
radioiodine-containing reagent, thyroid levels were presumed to reflect the sequestration 
of radioiodide produced by low rate of metabolic deiodination of compound. 
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Table 2.1. Cholesterol levels in the blood of apoE/LDLR knockout mice (n 
= 19) and control C57 mice (n = 8) maintained on normal chow diet for 8 
weeks (Average+ SE) 
mmol/L 
mg/dL 
Cholesterol level 
apoEILDLR knockout mice 
(n = 19) 
15.14 ± 0.89 
584.7 + 34.4 
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control mice 
(n= 8) 
2.95 + 0.16 
113.8 + 6.1 
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Figure 2.5. Radioactivity found in various organs 24 h after i.v. injection of 
125I-C21/AcLDL at 1.85 MBqlkg in apoE/LDLR knockout mice (n = 10) and 
control mice (n = 4). Results shown are mean+ SEM (* p < 0.05). 
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Figure 2.6. Radioactivity found in various organs 24 h after i.v. injection of 
125I-C21 emulsion at 3.33 MBq/kg in apoEILDLR knockout mice (n = 6) and 
control mice (n = 4). Results shown are mean+ SEM (* p < 0.05). 
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Table 2.2. Biodistribution of radioactivity in various tissues expressed as % 
injected dose/g tissue 24 h after i.v. injection of 1.85 MBqlkg 125I-
C2I/AcLDL or 3.33 MBq/kg 125I-C2I emulsion (Average± SEM) 
1251-C211 AcLDL group 125I-C21 emulsion group 
Tissue ( % injected dose per gram tissue ) 
apoEILDLR 
Control mice 
apoEILDLR 
Control mice 
knockout mice knockout mice 
(n=10) 
(n=4) 
(n=6) 
(n=4) 
liver 2.074±0.397 1.040±0.067 18.468±2.644 18.205±6. 789 
kidney 0.467±0.066 0.271±0.013 3.276±0.388 3.358±1.099 
adrenal gland 4.603±0.984 4.594±0.923 6. 700±2. 731 9.589±4.832 
spleen 0. 770±0.151 0.374±0.034 14.755±1.095 10.481±2.639 
lung 0.581±0.109 0.287±0.072 2.861±0.594 2.235±0.766 
blood 0. 778±0.181 * 0.093±0.008 9.671±1.195* 3.074±1.167 
fat tissue 0.584±0.160 0.434±0.045 0.464±0.1 09 0.851±0.524 
aorta 0.472±0.113* 0.042±0.016 2.392±0.464* 0.530±0.198 
* p < 0.05 
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Sudan N staining of the aorta was performed in order to visualize the 
atherosclerotic lesions. The red lipid stain is an indication of lipid-laden foam cells, a 
hallmark of early atherosclerosis. The phosphorimages, which reflect the level of 
radioactivity, and the Sudan N results for aortas are illustrated in Figure 2. 7. It is clear 
that the accumulation of radioactivity in the aortas of apoE/LDLR knockout mice as 
revealed by phosphorimages was superimposed on the lesion identified by the Sudan N 
staining. Both phosphorimaging and Sudan N staining exhibited negative results for the 
aortas of the control mice: neither accumulation of radioactivity nor atherosclerotic 
lesions were present. 
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2.4 Discussion 
It is now becoming clear that vulnerable atherosclerotic plaques are more closely 
associated with clinical acute coronary syndromes than vessel stenosis severity 
[McConnell, 2000; Cerqueira, 1999]. Hence, an earlier evaluation and intervention of 
atherosclerosis would be more effective in reducing the morbidity and mortality due to 
CVD. The atherosclerotic plaque prone to rupture is usually a modestly advanced lesion, 
not visible by traditional angiography [McConnell, 2000]. Therefore, reliable diagnostic 
technologies that can directly image atherosclerotic lesions or detect abnormalities of the 
vessel wall itself are urgently required. Radionuclide tracer imaging which takes 
advantage of targeted biological markers or specialized ligands appears to be one of the 
promising approaches for this purpose [Cerqueira, 1999]. It is known that macrophages 
play an important role in the formation of atheroslerotic lesions, thus modified LDLs, 
substrates of receptors present in macrophages, are considered to be promising. Previous 
studies have demonstrated the feasibility of using radiolabeled LDL or OxLDL as a tracer 
for experimental arterial lesions in animal models and human atheroslerotic plaques 
[Atsma et al., 1993; Lees et al., 1983; Lees et al., 1988; Iuliano et al., 1996]. However, 
when LDL or modified LDL is internalized into the targeted cells, it is rapidly degraded 
by lysosomal enzymes and then the radiolabeled protein residue is excreted, resulting in 
rapid clearance of the radiolabeled LDL or OxLDL from the lesion [Goldstein et al., 1979; 
Brown and Goldstein, 1983]. Attempts to overcome this problem have led researchers to 
study protein ligands that would remain in the cell once internalized [Pittman and Taylor, 
1986]. Since CEs are a major component of the lipophilic core of LDL, 1251-cholestryl 
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iopanoate e251-Cl), aCE analog, studied earlier by Counsell et al [DeGalan et al., 1988; 
Deforge et al., 1992], has been incorporated into AcLDL and evaluated as an imaging 
agent for the detection of atherosclerotic lesions in a rabbit model [Xiao2 et al., 1999]. In 
this work, C21, a novel analogue of Cl, was studied. Like Cl, C21 also possesses an 
enhanced hydrophobicity and is resistant to hydrolysis by lysosomal enzymes in cells due 
to the presence of the ether bond in the molecule [Xiao et al., 2003]. Furthermore, C21 
contains six iodines for radio labeling, which is twice the number available with CI, and 
therefore allows labeling with a higher specific radioactivity. After promising results 
were obtained in rabbits [Xiao et al., 2003], we used apoE and LDLR double knockout 
mice in this study to evaluate its in vivo behavior when incorporated into AcLDL. In 
addition, we prepared a chylomicron-like emulsion of C21 using phospholipids and highly 
unsaturated triglyceride-rich seal oil as the core lipid components, and compared its 
lesion-seeking ability with C21/AcLDL. Chylomicron is a type of triglyceride-rich 
lipoprotein responsible for transporting most dietary lipids from intestine to the blood: 
With a size range of 80-1 OOOnm in diameter, it is rapidly cleared from plasma by lipolysis 
and remnants uptake [Spady, 1992]. Although the liver is the main organ for the uptake 
of chylomicron remnants, extrahepatic tissues including the arterial wall are also involved 
in its clearance possibly through a receptor-mediated process (endocytosis or 
phagocytosis), such as apoE-binding receptors and scavenger receptors [Redgrave, 2001; 
Terpstra et al., 2000]. It has been reported that there is a clear relationship betweeri 
chylomicron metabolism and progression of atherosclerosis [Redgrave, 2001]. Emulsions 
with similar lipid composition and particle size as chylomicron will mimic' its 
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metabolizing pathway after intravenous administration, therefore we expect this 
formulation to deliver the radioiodinated C21 to atherosclerotic lesions. 
125I-C21 emulsion used in the experiment was freshly prepared, which was essential 
due to its thermodynamic instability. During the incubation of emulsion with AcLDL, 
there was an exchange of lipid components between them, resulting in the incorporation 
of 125I-C21 into AcLDL. The results from 1% agarose gel electrophoresis showed that the 
incorporation did not alter the integrity of AcLDL. As revealed by 6-20% SDS-PAGE, 
apoB-1 00 also remained intact, which is crucial for recognition of the particles by the 
scavenger receptor on the macrophages. When 125I-C21/AcLDL was examined by 
Sephadex® G-25 gel filtration, the radioactivity chromatogram was superimposed with 
that of protein, indicating that 1251-C21 was either incorporated into or tightly associated 
with AcLDL. The lipophilicity of C21 was thought to have facilitated its incorporation 
into the LDL lipid core. However, the incorporation efficiency ofC21 (200 molecules per 
AcLDL particle) was lower than that of CI (500 molecules per AcLDL particle) [Xiao2 et 
al, 1999]. This could be attributed to the larger molecular size ofC21. 
Gene targeting and transgenic technology have provided a series of mouse strainS 
with a wide range of lipoprotein profiles and susceptibility to atherosclerosis [Smith and 
Breslow, 1997; Dansky et al., 1999]. In this study, apoEILDLR double knockout :i:nice 
that are prone to the development of atherosclerotic lesions were used as an animal 
model. After 8 weeks on normal chow diet, the plasma cholesterol level of apoE/LDLR 
knockout mice (age 15-16 weeks) was 5 times as high as that of the control mice, and a 
few fatty streaks were already present at the aortic arch and branch points. Two weeks 
45 
later, 125I-C21/AcLDL or 125I-C2I emulsion was injected into mice (at 18-20 weeks of 
age). A higher radioactivity dose of 125I-C21 emulsion was used, because the targeting 
specificity of the emulsion formulation was estimated to be lower than that achieved from 
using 125I-C21/AcLDL. Tissue biodistribution studies performed 24 h after administration 
demonstrated that both 1251-C21/AcLDL and 125I-C2I emulsion were effective in targeting 
the early atherosclerotic lesions. Although the preparation process was more laborious, 
125I-C21/AcLDL, as we anticipated, showed better specificity than the emulsion. The 
radioactivity levels accumulated in the aorta of the atherosclerotic apoEILDLR knockout 
mice following administration of 125I-C21/AcLDL and 125I-C21 emulsion were 11 and 4.5 
times those found in the aorta of the control mice. A significant amount of radioactivity 
was also found in the blood of apoEILDLR knockout mice, which can be explained by 
their elevated blood cholesterol levels. The strong blood signal would likely provide a 
large background for in vivo detection. However, it should be noted that although the 
aorta appeared to contain a lower level of radioactivity than blood, the specific 
radioactivity in the atherosclerotic lesion, which occupied less than 25% of the aorta, 
would be at least four times as high as that of the aorta. Consequently, the specific 
radioactivity in the lesion would be higher than that found in the blood following 
administration of 125I-C21/AcLDL, while the specific radioactivity in the lesion after 
administration of 125I-C21 emulsion would be similar to that found in the blood. Even so, 
it is still important to study the blood clearance profile of 12sr-c21 in order to determine 
the appropriate time interval to perform the in vivo detection after administration of the 
radioimaging agent. An ideal time interval would be the time when the ratio of 
radioactivity in the suspected lesion to that in the blood is maximum or when there is 
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enou¢1 radioactivity accumulated in the suspected lesion and little radioactivity still in 
the blood. Further studies are required to address the above concern. Our results also 
indicated that significant amounts of radioactivity were presented in adrenal and liver 
following administration of 125I-C21/AcLDL. While it is known that the liver, being rich 
in scavenger receptors, can rapidly remove AcLDL [van Berkel et al., 1995], it is unclear 
what mechanisms are involved in the uptake of 125I-C21/ AcLDL by the adrenal gland, one 
of the steroid hormone-secreting tissues, especially when LDLR is deficient. Following 
administration of 1251-C21 emulsion, the highest level of radioactivity was found in the 
liver as expected, since . the liver is the main organ responsible for the metabolism of 
chylomicrons. As for the elevated level of radioactivity found in thyroid, which is a 
common drawback of all radioiodine-containing tracers, "cold" iodide such as Nal can be 
pre-administered prior to the proposed radioimaging agent in order to saturate the iodine-
uptaking capacity of thyroid. 
Sudan N staining was employed to reveal the gross distribution of atherosclerbtic 
plaques. As shown in Figure 2. 7, foamy cell lesions were formed throughout the arterial 
tree which is similar to that seen in human atherosclerosis. Histological examinatiol1S 
showed plaques of foam cells, cholesterol clefts and lipid pools, which resembled 
moderate human lesions (Figure 2.8). The radioactivity images of aorta samples revealed 
by ex vivo scanning using a phosphorimager were superimposed on the results from 
Sudan N staining, suggesting that 125I-C21/AcLDL and 125I-C21 emulsion selectively 
deposited C21 at the atherosclerotic regions. 125I-C21 was able to remain at the lesions, 
presumably because of the presence of the ether bond in the molecule of C21 which is 
resistant to lysosomal hydrolysis. If an appropriate radioisotope such as 1231 is used as a 
47 
substitute for 1251, the lesions could be visualized externally using appropriate imaging 
equipment. 
In summary, the results obtained in this study are promising. The selective uptake 
and retention of a radiolabeled polyiodinated probe, 125I-C2I, to early atherosclerotic 
lesions have been accomplished by using AcLDL or chylomicron-like emulsion as a 
delivery system. However, more studies are required to address a number of concerns. 
For example, the blood clearance of the radioactive probe and the optimal time interval 
for achieving the maximum target-to-background ratio are yet to be determined. 
Moreover, not all vulnerable plaques may be imaged with the radiolabeled cholesterol 
analogue because some rupture-prone lesions contain a thin fibrous cap and lack lipid 
pool. In addition, nuclear imaging has a relatively low spatial resolution (5-10 mm:), 
which will pose a significant challenge to resolve some subclinical atherosclerotic lesions 
(often< 1 mm diameter) compared to the much large blood-filled vascular lumen (20-30 
mm diameter in the aorta, 3-4 mm thick in the coronary arteries). 
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Figure 2.8. Light micrograph (xlOO) of a cross section of an Hematoxylin 
and Eosin (H&E) stained atherosclerotic lesion from the aortic arch of an 
apoE/LDLR knockout mouse. Lesion part, containing foam cells, 
cholesterol clefts, and lipid pools (LIP), peeled off from the wall (W) of the 
aorta during the preparation process of the sample. The bar represents 100 
Jlm. 
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Chapter 3. In vitro gene transfection by malaria peptide 
targeted cationic liposome/protamine/DNA (LPD) complexes 
3.1 Introduction 
Gene therapy, a new pharmacotherapeutical concept, originally addresses the root 
causes of many genetic disorders by replacing the defective or missing genes with correct 
genes and subsequently expressing functional proteins [Crystal, 1995; Jain, 1998; Ledley, 
1996]. However, it has long been postponed by the lack of appropriate carriers or 
vehicles used to deliver therapeutic genes into the right cells/tissues/organs. In order to 
achieve successful gene therapy, there are at least two delivery systems being examined 
as carriers: viral and non-viral vectors. Although viral vectors are highly efficient, they 
usually cause a number of safety problems, such as immune responses, inflammatory 
reactions, potential recombination or complementation and other toxicities. In addition, it 
is difficult to make large quantity of viral vectors [Scherman et al., 1998]. Non-viral 
vectors, on the other hand, are safer and easier to make although they have lower 
transfection efficiency than viral vectors. The advantages of using non-viral vectors, 
especially cationic liposomal systems, have recently attracted more research efforts 'on 
their development [Scherman et al., 1998; Pedroso de Lima et al., 2001]. LPD complex is 
one of the widely employed formulations showing great potential in the area of gene 
therapy [Li et al., 2000]. However, both viral and non-viral vectors lack homing devices 
to direct DNAs to the specific organ(s) upon direct in vivo administration. The 
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distribution of the delivered genes is generally throughout the whole body of 
experimental animals [Zhu et al., 1993; Templeton et al., 1997]. Targeted delivery thus 
needs to be explored to achieve greater gene expression in specific organs and to 
minimize adverse effects. 
Malaria sporozoites enter into human liver just a few minutes after mosquito biting. 
The speed of infection and target cell selectivity suggest that the invasion is mediated by 
specific ligand-receptor endocytosis. The major surface protein of malaria parasites 
(Plasmodium falciparum), the circumsporozoite (CS) protein, contains two conserved 
domains (region I and II) and a domain from CS II was found to be implicated in the 
selective binding to mammalian hepatocytes [Cerami et al., 1992; Chatterjee et al., 1995]. 
In this study, we hypothesized that LPD coupled with the peptide derived from CS 'II 
would be specifically delivered to the liver after intravenous administration. A 
palmitoy1ated 24 amino acid malaria peptide was thus designed according to the 
published sequence [Cerami et al., 1992; Suarez et al., 2001] (Figure 3.1A). The fatty 
acid moiety is used to serve as a lipid-chelating anchor. To investigate the transfection 
ability of this peptide-LPD complex in vitro, a plasmid bearing chloramphenicol 
acetyl transferase (CAT) or enhanced green fluorescent protein (EGFP) encoding reporter 
gene was used to prepare LPD and then examined in cultured HepG2 (human hepatoma 
cell line) and Hela cells (human cervical carcinoma cell line, as a control). CAT-LPD 
preparations with or without the peptide were also injected into wild-type mice as a 
preliminary evaluation of feasibility of their use for in vivo transfection. 
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Figure 3.1A. Sequence of the palmitoyl derivative of modified peptide (24 
amino acids) derived from the domain II of circumsporozoite protein (CS) of 
malaria parasites (Plasmodium falciparum ). 
The ultimate objective of this project, although beyond the work conducted in this 
chapter, is to deliver the mouse LDLR (mLDLR) gene to the liver of LDLR-knockout 
mouse, an animal model closely resembling human FH conditions. FH is one of the most 
prevalent genetic diseases, and is characterized by a high level of plasma cholesterol and 
premature atherosclerosis. The culprit is the malfunction of LDLR resulting from a 
mutation in the gene specifying it [Goldstein et al., 2001]. Normally, LDLR is expressed 
mainly on the surface ofhepatocytes (constituting more than 70% of the body's LDLR) 
and plays a critical role in the mechanisms underlying the homeostasis of cholesterol. 
Gene therapy is an ultimate way for the treatment of FH. It has been shown in clinical 
trials to be useful in lowering plasma cholesterol and reducing atherosclerosis risk, but 
still needs further study to obtain practical, satisfactory results, especially with respect to 
the safety concerns of viral delivery systems [Kawashiri and Rader, 2000]. The success 
of the in vivo delivery of the malaria peptide-LPD complex (D = LDLR gene) and 
subsequent expression of LDLR is expected to correct the elevated plasma cholesteroi 
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level of LDLR knockout mice. Positive results might render the malaria peptide-LPD 
complex as a promising non-viral delivery alternative for the gene therapy ofFH. 
3.2 Materials and methods 
3.2.1 Materials 
1,2-diolelyl-3-trimethylammonium-propane (DOTAP, Figure 3.1B) and mini-
extruder including different sizes of polycarbonate membranes were purchased from 
Avanti Polar Lipids (Alabaster, AL, USA). Protamine sulphate Grade X from salmon, 
cholesterol, Dulbecco's Modified Eagle's Medium (DMEM) and Ix trypsin-EDTA 
solution were obtained from Sigma-Aldrich Canada Ltd. (Oakville, ON, Canada). Fetal 
bovine serum (FBS) was purchased from Hyclone (Logan, UT, USA) and the antibiotics 
were from Mediatech, Inc. (Herndon, VA, USA). Chloroform and N,N-
dimethylformamide (DMF) were obtained from Fisher Scientific (Ottawa, ON, Canada). 
CAT ELISA (enzyme linked immunosorbent assay) kit was purchased from Roche 
Diagnostics (Laval, Quebec, Canada). Bio-Rad (Mississauga, ON, Canada) DC 
(detergent compatible) protein assay reagent was used to determine protein concentration. 
The palmitoylated malaria peptide derivative was synthesized by Genemed Synthesis, 
Inc. (San Francisco, CA, USA). The oligonucleotide primers used in the preparation of 
plasmids were synthesized by Operon, a Qiagen company (Alameda, CA, USA). 
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Figure 3.1B. Structure of 1,2-diolelyl-3-trimethylammonium-propane 
(DOTAP). 
3.2.2 Cell culture 
HepG2 cells and Hela cells were generously provided by Dr. T. Michalak and Dr. 
A. Pater (Faculty of Medicine, Memorial university of Newfoundland), respectively. 
They were maintained in DMEM supplemented with 10% FBS, 100 IU/ml penicillin and 
100 mg/ml streptomycin at 37°C with 5% C02• 
3.2.3 Construction and purification of reporter gene plasmid 
CAT eDNA fragment (657 bp) was released from pBlueBac4.5/CAT (Invitrogen 
Canada Inc., Burlington, ON, Canada) with endonuclease Hindiii and subcloned into a 
mammalian expression vector pcDNA3.1(-)/Myc-HisA (Invitrogen). The positive clone 
was screened and examined by EcoRI digestion, then amplified in TOP 10 strain of E. 
Coli. A QIAGEN Plasmid Mega kit (Valencia, CA, USA) was used to isolate and purify 
CAT plasmid according to the manufacturer's instruction. EGFP plasmid was a kindly 
gift from Dr. K. Mearow (Faculty of Medicine, Memorial University ofNewfoundland). 
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All final plasmids were kept in TE buffer {Tris-HCl 10 mM, EDTA 1 mM, pH 8.0) at 
3.2~4 Preparation of cationic liposome 
DOTAP-cholesterol liposome (1:1 molar ratio) was prepared according to the 
method described by the L. Huang group [Li et al., 2000] with minor modification 
[Templeton et al., 1997]. Briefly, the lipid mixture was dissolved in HPLC-grade 
chloroform in a 50 ml round-bottomed flask and dried under vacuum using a rotary 
evaporator for 30 min. The thus formed thin lipid film was further desiccated under 30 
mmHg vacuum for 1 h. The residue was then re-suspended with 5% dextrose water 
(D5W) and vortexed. The final concentration of DOT AP was 10 mg/ml. The hydrated 
lipid suspension was rotated at room temperature for 50 min and kept under argon 
overnight for aging. After 5 min low-frequency sonication (Branson 5200, Branson 
Ultrasonics Corporation, Danbury, CT, USA) and 10 min heating at 50°C, the lipid 
suspension was sequentially extruded through polycarbonate membranes with decreasing 
pore sizes of0.6, 0.2 and 0.1 J.llD using a mini-extruder. The obtained liposome was kept 
under argon gas at 4°C. 
3.2.5 Preparation of cationic liposome/protamine/DNA (LPD) complex 
Two slightly different methods were used to prepare LPD. First, LPD was 
prepared as described by a published protocol [Li et al., 2000; Templeton et al., 1997~ 
with minor modification. In brief, the liposome obtained above was mixed with small 
volume of protamine (5 mg/ml stock in D5W) and the mixture was incubated for 5 min at 
room temperature. CAT or EGFP plasmid (0.65 mg/ml) was diluted in equal volume of 
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D5W and then gently added to the liposome-protamine solution. The mixture was · 
incubated at room temperature for 20 min to form LPD complex (1 J.Lg DNA : 0.6. J.Lg 
protamine : 8.4 Jlg DOTAP I 3.4 J.1l volume), which is referred as LPD(a). The LPD(a) 
samples were subjected to negative stain electron microscopy (EM) examination. LPD 
was also prepared by the following method. Liposome-protamine mixture and plasmid 
were respectively diluted in large equal volume of serum/antibiotics-free DMEM first, 
and then combined together, followed by 20 min incubation at room temperature (under 
the same ratio as the above in a final volume of 100 J.Ll). The LPD prepared by the second 
method is referred as LPD(b ). 
3.2.6 Preparation of complexes of LPD coupled with the palmitoylated malaria 
peptide 
LPD was coupled with the palmitoylated malaria peptide by the following two 
different methods: (I) Peptide dissolved in DMF (100 J.Lg/J.Ll) was diluted using D5W and 
added to the LPD( a) preparation at different ratios (0.5, 1, 2, 5, 10 J.Lg peptide/ 1 J.Lg DNA) 
with final DMF concentration less than 1% (v/v). The mixture was slowly mixed using a 
pipette tip and incubated at room temperature for 15 min to obtain a peptide-LPD 
complex referred as LPD-pep; (II) Peptide was introduced to liposome during . th~ 
hydration step in the preparation of the liposome. As described in section 3 .2.4, after thin 
lipid film was formed and dried, D5W mixed with the peptide in DMF was added and 
vortexed. The liposome-peptide suspension was then extruded and proceeded with· the 
same procedures as those for LPD(a) or LPD(b); the thus prepared complex is referred as 
L-pep-PD(a) or L-pep-PD(b) (DNA= CAT). The final ratio of peptide in these L-pep-PD 
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preparations was 1 Jig peptide I 1 Jig CAT DNA. DMF-LPD complexes without peptide 
were also prepared as a control using the above protocols. 
3.2. 7 Characterization of liposome and LPD complex 
The particle size and zeta-potential of cationic liposome or LPD preparations were 
determined by four-angle dynamic laser light scattering using a Coulter® Delsa 440SX 
zeta potential analyzer (Beckman Coulter Inc., Miami, FL, USA). The samples were 
diluted with deionized water (1 :200, v/v) and three successive size determinations were 
made on each sample. 
3.2.8 In vitro transfection 
All the following transfection experiments were done in antibiotic-free DMEM. 
HepG2 cells (3x105 cells/well) and Hela cells (1x105 cells/well) were seeded into a 24-
well plate with DMEM containing 10% FBS. When they were 85-95% confluent after 36 
h, culture medium was changed to 300 J1l FBS-free DMEM, and LPD or malaria peptide-
LPD preparations were added (1 Jig DNA/well) and incubated for 6-8 h. Then cells were 
washed 3 times with phosphate buffered saline (PBS, pH=7 .4) and incubated in DMEM 
containing 10% FBS. Thirty-six hours later, cells transfected, with CAT plasmid were 
lysed with 300 J.Lllysis buffer provided in CAT ELISA kit and the protein concentration 
was determined by Bio-Rad DC protein assay. Expression of CAT protein was measured 
by a CAT ELISA kit according to the manufacturer's instruction. For EGFP transfection, 
harvested cells were fixed by 1% paraformaldehyde-PBS solution and examined by flow 
cytometry. The percentage of transfected cells expressing EGFP-associated fluorescence 
was analysed by WinMDI software (by Joseph Trotter). 
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The transfection experiment was also performed in 300 J..1l DMEM containing 10% 
FBS for 24 hrs instead of in serum-free medium. 
3.2.9 In vivo delivery and gene expression 
Three 6-week-old C57BL/6 mice (female, - 20g) provided by Dr. C. Kovacs 
(Faculty of Medicine, Memorial University of Newfoundland) were used in this very 
preliminary in vivo experiment. Two mice were injected via the tail vein with 85 J.Lg CAT 
gene formulated in LPD(a) in a total volume of 200 J.Ll using a 27-gauge syringe needle, 
and one mouse was injected with the same amount of LPD coupled with 35 J.Lg malaria 
peptide in LPD-pep formulation. Forty-eight hours following i.v. injection, the mice were 
sacrificed by over-exposure with diethyl ether, and heart, lung, liver, spleen, kidney, 
pancreas, small intestine, adrenal gland, bone marrow, and skeleton muscle were 
collected. The organs were washed with cold saline and quickly frozen with liquid 
nitrogen. Tissue extracts were prepared by homogenization of respective tissues in lysis 
buffer (0.05% Triton X-100, 2mM EDTA, 0.1 M Tris, pH 7.8) using a PELLET 
PESTLE® mixer (Kimble/Kontes, Vineland, New Jersey, USA) followed by 30 :min 
incubation on ice. The homogenates were then centrifuged at 14,000g for 10 :min at 4°C. 
The supernatant was assayed for CAT activity using a CAT ELISA kit and protein 
content was determined as described above. 
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3.2.10 mLDLR eDNA cloning and construction into an expression vector 
Complete mLDLR eDNA was amplified by RT-PCR from C57BL/6 mouse liver 
RNA using the following primers: 5' -GATCCAGTGTTTGCAGCGGG-3' and 5'-
CGAATTTCAAGCACAGCCAGTAGC-3 '. Amplification products were then cloned. 
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into a TA vector pCRII (Invitrogen). Automatic DNA sequencing was performed by Sick 
Children Hospital (Toronto, ON, Canada). The primers designed for sequencing were: 
mLDLRseqMl: 5' -GATCCTCACTGTGCTTCG-3' 
mLDLRseqPl: 5' -GATGGCAAGTGCATCTCC-3' 
mLDLRseqP2: 5'-TTTGGACAACAATGGTGG-3' 
mLDLRseqP3: 5' -AAGGGCGTAAAGAGGAGG-3' 
The mLDLR nucleotide sequence and deduced amino acid data were directly 
submitted to the Genebank (accession number AF425607). The complete eDNA of 
mLDLR was then released from pCRII vector through Xhol-Hindlll restriction 
endonuclease digestion and subcloned into an eukaryotic expression vector pcDNA3.1(-) 
/Myc-HisA (Invitrogen). 
3.3 Results 
3.3.1 Construction of CAT plasmid 
Figure 3.2A shows the scheme of the structure of CAT plasmid. Approximately 
657 bp CAT eDNA fragment which contains endonuclease EcoRI was inserted into a 
mammalian expression vector pcDNA3.1(-)/Myc-HisA at the Hindlll site. As shown in 
Figure 3.2B, successful construction of CAT plasmid was demonstrated by the restriction 
endonuclease EcoRI digestion analysis. Six colonies of CAT plasmid minipreps were 
examined by 1% agarose gel electrophoresis stained with ethidium bromide (EtBr) after 
EcoRI digestion. It was found that colonies #2, 4, and 6 were positive with right 
orientation of CAT insertion. Colonies # 1 and 3 were positive but with reverse 
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orientation of CAT insertion. Colony #5 was negative. Clone #4 was then chosen to be 
amplified and purified to prepare LPD. 
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I 
pcDNA3.1(·)/ 
Mye-Bis A, B, C 
S.Skb 
Figure 3.2A. Construction scheme of CAT eukaryotic expression plasmid. 
CAT gene was released from pBlueBac4.5/CAT with endonuclease Hindlll 
and subcloned into the mammalian expression vector pcDNA3.1(-)/Myc-
His A. 
61 
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..... 572bp 
..... 287bp 
Figure 3.2B. Restriction enzyme (EcoRI) digestion analysis of CAT 
plasmid minipreps with 6 colonies. The 1% agarose gel was stained with 
EtBr and visualized under UV. 
+ Colonies #2, 4, 6 were positive with right orientation of CAT insertion 
and clone #4 was amplified to prepare LPD. 
+ Colonies #1, 3 were positive but with reverse orientation of CAT 
insertion. 
+ Colony #5 was negative. 
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3.3.2 Characterization of LPD preparations 
DOTAP-cholesterolliposome and LPD were prepared, following which the size 
and zeta-potential of the resultant particles were measured. As shown in Table 3.1, after 
final extrusion through 0.1 J.Un-pore size membrane, the size of cationic liposome was 
found to be about 130 nm and the zeta-potential was 43 mv. When kept at 4°C for 10 
weeks, the particle size of liposome stayed almost unchanged, indicating relatively higher 
stability of cationic liposomes compared to the traditionalliposomes (stable only for 3-4 
days ). LPD formulation showed an average particle size of 430 nm which was somewhat 
bigger than that (135 nm) reported by the L. Huang group [Li et al., 1998], indicating that 
aggregation might have occurred with our LPD preparations despite the use of the 
suggested ratio of lipid, protamine and DNA. The zeta potential of LPD was found to be 
26 mv, which represented a positive charge carried by final particles. 
Electron micrographic analysis of the LPD(a) preparation showed similar 
morphology as reported in the literature [Li et al., 2000]. As seen in Figure 3.3, the LPD 
preparation is heterogeneous in population, containing both liposome-protamine-DNA 
complexes and free liposomes. According to the description given in the above literature, 
the smaller, compact particles are presumed to be LPD. 
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Table 3.1. Particle size and zeta-potential of cationic liposome and LPD 
complex (mean+ SD) 
DOTAP-cholesterolliposome 
Liposome/protamine/DNA 
(LPD) 
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Size.(nm) Zeta-potential (mv) 
131 + 18 43.1 + 14.5 
430 + 61 26.4 + 9.0 
Figure 3.3. Negative stain transmission electron micrograph of LPD(a) 
complexes, showing both free liposomes (open arrows) and condensed LPD 
particles (filled arrows). The bar represents 100 nm. 
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3.3.3 In vitro gene transfection 
All LPD preparations used in in vitro experiments were complexed as 1 J.Lg DNA : 
0.6 J.Lg Protamine: 8.4 J.Lg DOTAP and no obvious cytotoxicity was observed during the 
experiment. As shown in Figure 3.4A and 3.4B, LPD (D = CAT gene) preparations 
resulted in similar pattern of CAT expression in both Hela and HepG2 cell lines, and Hela 
cells (Figure 3.4A) exhibited more sensitivity to transfection than did HepG2 cells 
(Figure 3.4B). When malaria peptide was mixed with LPD complexes for targeting 
purpose (LPD-pep preparations}, there was a dose-dependent effect: lower concentration 
of peptide showed higher transfection efficiency. An optimal dose of peptide (1 J.lg 
peptide/1 J.lg DNA) was therefore used in the subsequent experiments. In HepG2 cells, 
peptide-LPD formulations led to 1.5 times (LPD-pep) or 5 times (L-pep-PDa) higher 
CAT expression than LPD itself (LPDa), respectively. However, no difference was 
observed in Hela cells for LPD-pep and there were only 1.5 times higher CAT products 
for L-pep-PDa preparation than LPDa. The DMF-LPD controls did not show either an 
increase or a decrease in the transfection results (data not shown). 
When LPD was prepared with a large volume of serum free medium as diluent to 
form LPDb or L-pep-PDb, transfection efficiency dramatically increased. Again, L-pep-
PDb showed a better result than LPDb in HepG2 cells, while in Hela cells, the 
transfection difference between LPDb and L-pep-PDb was not obvious. 
Another reporter DNA, EGFP, was used to prepare only LPD(a) or LPD-pep during 
the early experiments. The transfection results of EGFP in cells could be observed under 
the fluorescence microscope and directly examined by flow cytometry analysis because 
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EGFP itself is a fluorescence-emitting protein. As revealed in Figure 3.5, the overall 
transfection efficiency of our formulations was found to be very low. Only 0.6-3% cells 
were positively transfected when measured by flow cytometry. Apparently, LPD-pep 
resulted in a higher EGFP expression than LPD in HepG2 cells, whereas no obvious 
difference was found in Hela cells. 
As most research studies suggested, the above transfection experiments were all 
done in serum and antibiotic free medium for 6-8 h, when the cells were in starvation 
status. To overcome this problem, we also tried using DME medium containing 10% 
FBS during transfection, and no obviously different results were obtained (data not 
shown), indicating that serum had no apparent destabilizing effect on the LPD or peptide-
LPD preparations we used. 
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Figure 3.4A. CAT expression after in vitro transfection with various LPD 
or malaria peptide-LPD preparations in Hela cells. The experements were 
conducted at least 3 times independently and the results are the mean values. 
Standard errors varied from 2% to 20% of the mean. 
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B. 
HepG2 cell 
., 
I>eptide Gng.-/, 
,.,. '"'ell) 
IIILPD-pep 
.LPDa 
lllliL-pep-PDa 
OLPDb 
.L-pep-PDb 
Figure 3.4B. CAT expression after in vitro transfection with various LPD or 
malaria peptide-LPD preparations in HepG2 cells. The experements were 
conducted at least 3 times independently and the results are the mean values. 
Standard errors varied from 2% to 25% of the mean. 
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3.3.4 In vivo gene transfer results 
Systemic CAT DNA delivery and gene expression were achieved using LPD( a) 
formulation at a dose of 85 JJ.g DNA in a 200 J!l final volume. Forty-eight hours post-
injection, all the organs examined exhibited transgene {CAT) expression. The lung was 
found to express the highest level of CAT protein, followed by the heart and bone marrow 
(Figure 3.6). Other organs including the liver showed much less sensitivity to the 
transfection than the lung. When LPD-pep formulation with 35 JJ.g of peptide and the 
same amount of CAT DNA was examined for liver targeting effects in one mouse, the 
pattern of CAT distribution in various organs was identical with that following LPD 
administration. However, there was no increased CAT production found in the liver 
compared to that after injection of LPD without the peptide, indicating that the malaria 
peptide in LPD-pep formulation at a 35 JJ.g dosage failed to deliver more LPD to the liver 
after systemic administration in this very preliminary experiment. 
3.3.5 Cloning of mLDLR eDNA 
mLDLR eDNA was successfully cloned. Figure 3.7 shows the screening result of 
positive pCRII-mLDLR colonies after endonuclease EcoRI digestion. Clone #3 showed 
bands of 0.8, 2.2, and 3.9 kb which were considered to be a positive construction. 
Complete sequence of mLDLR eDNA was examined and the accession number of 
mLDLR sequence by GeneBank is AF425607 (2855bp). The amino acid sequence 
deducted from mLDLR eDNA has 78% homogeneity as human LDLR according to 
calculation using OMIGA software (Intelligenetics Inc.). mLDLR plasmid was then 
constructed using an eukaryotic expression vector pcDNA3.1(-)/Myc-HisA and stored at 
-20°C prior to use. 
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Figure 3.6. CAT expression in various organs 48 h after intravenous 
injection of LPD(a) complex into C57BL/6 mice (n = 2). CAT production 
was normalized to protein concentration in the tissue extracts and is 
presented as the mean value. Individual data from each mouse was also 
showed: • mouse 1; • mouse 2. 
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Figure 3.7. Screening of positive pCRII-mLDLR colonies was achieved by 
EcoRI digestion of plasmid minipreps. Positive construction (#3) showed a 
pattern of -Q.8kb, 2.2kb and 3.9kb (vector) bands. The ladder (M) is a 1 kb 
molecular size standard from Invitrogen. 
74 
3.4 Discussion 
Gene therapy represents an important advance in the treatment of both inherited 
and acquired diseases. However, success of human gene therapy largely depends upon 
the development of delivery vehicles or vectors which can selectively deliver therapeutic 
genes to target cells with efficiency and safety [Walsh, 1998]. In the context of liver 
disease, such as genetic disorders (e.g. FH), metabolic disorders, viral hepatitis, and liver 
cancer, somatic gene therapy strategies have been suggested and shown some positive 
therapeutic effects [Nunes and Raper, 1996]. There are two general approaches to 
performing liver-targeting gene therapy: ex vivo and in vivo methods. While the ex vivo 
approach has generally used recombinant retroviruses as a gene delivery vehicle, the in 
vivo method, which is based on both viral and non-viral vectors, is more attractive 
because of its simplicity and reduced risk and expenses. Cationic liposomes are one' of 
the more promising non-viral vectors for in vivo gene therapy [Mahato et al., 1997],'and 
when labeled with a ligand which can be selectively recognized by receptors··· ori 
hepatocytes, they may be specifically delivered to the liver following systemic 
administration. 
In this study, LPD was chosen as a delivery vector for reporter genes because it had 
been shown to provide improved gene transfer activity both in vitro and in vivo [Gao 'arid · 
Huang, 1996; Li and Huang, 1997; Li et al., 1998]. As a type of cationic liposome-ba8ed 
vector, LPD consists of a ternary complex ofDOTAP : cholesterolliposome, polycationic 
protamine with DNA-condensing activity, and plasmid DNA. LPD had been found to be 
small, compact particles with a core of protamine-condensed DNA coated with a lipidic 
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shell, very much like enveloped viruses. This unique structure was shown to be less 
prone to aggregation and offer better protection of plasmid DNA against enzymatic 
digestion, therefore could dramatically increase the stability and transfection efficiency of 
liposome-DNA formulation [Sorgi et al., 1997]. Like other lipid-DNA complexes, some 
characteristics ofLPD, including the particular concentrations of cationic lipid, protamine 
sulfate and DNA, final particle size and charge, and even the addition order of the 
components during preparation, were all considered to be influential to the transfection 
efficiency [Ross and Hui, 1999]. The LPD used in our studies consisted of 1 J.Lg DNA : 
0,6 J.Lg protamine : 8.4 J.Lg DOTAP, which was shown to be an optimized form for in vivo 
gene transfer via intravenous administration [Li et al., 2000; Birchall et al., 2000]. 
Most liposomal formulations are essentially colloidal systems, and thermodynamic 
instability is their inherent characteristic [Lasic and Templeton, 2000]. However, 
DOT AP-cholesterolliposome prepared in this study was able to retain its particle size of 
• 130 nm for at least 10 weeks. The high positive charge (zeta-potential43 mv) is believed 
to contribute to its greater stability via the electrostatic repulsion between particles. In the 
case of LPD, it was reported to have a particle size of around 135 nm because of the 
condensation capability of protamine, which had been considered crucial for its increased 
transfection efficiency [Li and Huang, 1997; Li et al., 1998]. Although the same method 
was followed in our LPD preparations, the average particle size (430 nm) was not' a8 
small as expected, suggesting that aggregation of the resultant complexes might exist 
[Radler et al., 1997]. The large DNA-liposome aggregates could diminish the 
transfection activity of LPD formulations. However, production of transfected CAT gene 
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in our experiments cannot be directly compared with luciferase used in the L. Huang's 
group [Templeton et al., 1997]. It has also been shown that LPD is a heterogeneous 
population containing excess amounts of free (empty) liposomes and also small amounts 
of lipid/DNA complexes. The free liposomes are essential for maximal gene expression 
in intravenous gene delivery because they can neutralize the action between the plasma 
components and LPD complexes [Li et al., 1998]. EM examination of the LPD 
preparation confirmed its heterogeneity and showed some condensed LPD particles and 
free liposomes. 
The 24-amino acid malaria peptide derived from malaria CS II region was modified 
by attaching a palmitic acid to its N-terminal in order to increase the lipophilicity of the 
peptide. Theoretically, the fatty acid tail of the peptide is capable of incorporating into 
the lipid bilayers of the liposome, projecting its amino acid part on the surface of the 
liposome particle. At the time when the project was designed, we were expecting to 
conjugate the peptide with liposome by mixing the peptide with lipids (DOT AP and 
cholesterol) in chloroform during the first step of preparation of liposome. However, the 
synthesized palmitoylated peptide was found to be poorly dissolved in many orgamc 
solvents such as chloroform, methanol, isopropanol, and acetone, except in DMF. W ~ 
therefore had to use DMF as a solvent of the peptide and control the final concentration of 
DMF in LPD formulation (in D5W) less than 1%. As described in the method section: 
two different protocols, other than what we expected, were tried to prepare peptide-LPD 
complexes. They were referred as LPD-pep or L-pep-PD, respectively, according to the 
tum of adding the peptide during the preparation process. Although the small amount of 
DMF neither showed toxicity to the cultured cells nor affected the transfection results of 
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LPD, it is unclear what interaction is underlying between the peptide and cationic 
liposome under such conditions. 
The in vitro transfection experiments were performed usmg different LPD 
preparations. It was found that the LPD preparations were able to transfect cultured cells 
and result in certain level of reporter gene expression without visible toxicity. Compared 
to LPD(a), LPD(b) resulted in a considerably higher amount oftransgene production, 5 
times higher in HepG2 cells and 2 times higher in Hela cells, respectively. It is difficult 
to explain this observation because the only difference between these two preparations is 
the final mixing method of plasmid DNA with liposome-protamine mixture (see the 
Materials and methods section). However, the complexing volume ofliposome and DNA 
has been reported to be one of the important parameters for transfection efficiency 
[Staggs et al., 1997]. In addition, the LPD preparations showed equivalent transfection 
efficiency in cultured cells under both serum free and serum containing conditions. This 
can be considered as an advantage of the LPD formulation because it is not needed to 
eliminate serum during transfection, therefore protecting cells from starvation. 
Furthermore, the transfection time can be extended when necessary. 
The malaria peptide-LPD complex was prepared by two protocols. First, different 
amounts of peptide were added into the LPD(a) preparation to get what referred as LPD..:. 
pep, and a dose-dependent transfection result was observed in both cells. It was foood 
that higher dosage of peptide led to a lower level of transfection, which is possible due to 
the following reasons: (1) a competitive inhibition between LPD-pep complex and free 
peptide in the LPD-pep preparation. It is reasonable that higher dosage of peptide coUld 
provide more free peptide that were not conjugated with LPD particles; (2) probable 
78 
hemolytic activity of the short peptide [Hwang and Vogel, 1998]. An optimal dose of 
peptide (1 Jlg peptide/Jlg DNA/well) showed the highest level of reporter gene expression 
and therefore was used in the subsequent experiments. In addition, the LPD-pep 
formulation was found to produce only 1.5 times reporter gene activity as high as that 
from LPD(a) itself in HepG2 cells, although there was no difference found in control 
Hela cells. On the other hand, when prepared as L-pep-PD(a) formulation in which the 
peptide was added into the lipid during the hydration step of the liposome preparation, the 
transfection efficiency in HepG2 cells was found to be obviously higher, 5 times as high 
as that ofLPD(a) without the peptide. In Hela cells, L-pep-PD(a) also resulted in almost 
2 times elevated level of transfection compared to LPD( a), suggesting that Hela cell 
appeared to possess certain level of receptors for malaria peptide [Ding et al., 1995]. The 
above results showed the potential targeting effect of the malaria peptide to the liver cells: 
However, as mentioned before, the association between the peptide and the liposoine 
remains unknown. It is hard to explain the different effects resulted from LPD-pep and 
L-pep-PD(a). From their preparation method point of view, L-pep-PD(a) is obviously 
more possible than LPD-pep to provide the chance for the peptide to be associated with 
liposome, although it is also likely that the peptide may be incorporated into the inner 
layer of the liposome instead of the surface. Another intricate observation is the fact that 
when the transfection efficiency was considerably increased using the LPD(b) preparation. 
(compared to LPD(a)), L-pep-PD(b) did not show more improved result than LPD(b) in 
not only Hela cells but also HepG2 cells. 
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The preliminary in vivo experiment was carried out using only LPD(a) and LPD-
pep preparations. It is not surprising that LPD-pep did not lead to increased transfection 
activity in the liver after intravenous delivery based on the above in vitro results. The 
main significance of this preliminary test is to investigate the in vivo behaviour of our 
LPD preparation. It was found that, as the results published in the literature [Zhu et al., 
1993; Liu et al., 1997], the LPD preparation in our studies resulted in a similar 
biodistribution trend of the reporter gene in the body, in which the lung appeared to have 
the highest level of transfection activity. 
In summary, the cationic DOTAP-cholesterol liposome/protamine/DNA (LPD) 
preparations could transfect cultured cells in vitro, as well as different organs after 
systemic delivery into mice. A certain level of gene expression had been achieVed 
without visible toxicity. However, the transfection efficiency of cationic liposome 
vectors is still much lower than that of viral vectors although LPD had been shown to be 
an improved non-viral formulation. Malaria peptide, when prepared as peptide-LPD 
complex, showed some targeting effect in human hepatoma cells; however, these results, 
although promising, were somewhat inconsistent. There is definitely a requirement in 
future work to figure out more detail information about the peptide-LPD formulations iri 
order to further understand their association and accordingly optimize the preparation 
protocol. The insolubility of the palmitoylated peptide was a major concern because! the 
introduction of DMF might affect the interaction between the peptide and the liposome. 
In future, it is probably required to re-design the modification of the peptide, for example; 
to conjugate the peptide with some other lipophilic chain such as cholesterol. 
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After a peptide-LPD formulation is proved significantly efficient in liver targeting 
both in vitro and in vivo via the reporter gene, the transfection experiments will be 
conducted in LDLR knockout mice using the mLDLR plasmid in same preparation to 
explore the possibility of liver-specific gene therapy strategy for FH, the final objective of 
this project. 
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Chapter 4. Antiproliferative effect of 3' ,5'-dipalmitoyl-5-
tluorodeoxyuridine incorporated into low density lipoprotein 
on human cervical cancer cells 
4.1 Introduction 
In chemotherapy of cancer, toxicity and drug resistance remain as the major 
challenges. The narrow therapeutic window of antineoplastic drugs hampers the 
administration of fully effective doses. A therapeutic strategy in which antineoplastic 
drugs are associated with carriers that are selectively taken up by tumor cells may 
diminish side effects and allow the administration of more effective doses [Tomlinson, 
1987]. 
The receptor for LDL is an attractive target for the selective delivery of 
antineoplastic drugs to tumors because it has been found that many tumors of different 
origins express elevated levels of LDLR [Vitols, 1991; Markel and Brook, 1994]. 
Especially tumors of gynecological origin and myeloid leukemic cells, but also colon, 
kidney, lung, and prostate tumors, were found to express exceptionally high amounts of 
LDLRs [Firestone, 1994]. The elevated expression ofLDLRs on cancer cells is probably 
a result of their accelerated proliferation and to meet their increased demand for 
cholesterol. LDL, the predominant cholesterol-transporting lipoprotein in human, is a 
spherical particle of about 23 nm in diameter that consists of a hydrophilic shell· of 
phospholipids and cholesterol, and a lipophilic core of mainly cholesterol esters. A large 
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part of the particle surface is covered with the apoB-1 00, which can be specifically 
recognized by the LDLR. After internalization of LDL via its receptor, the particle is 
degraded in the lysosomes and the cholesterol is released into the cytoplasm [Brown and 
Goldstein, 1986]. 
The fluoropyrimidine antimetabolite 5-fluoro-2'-deoxyuridine (FUdR) has been 
used extensively for the clinical treatment of carcinomas of the ovary, breast, and 
gastrointestinal tract [Henn et al., 1993; Xia et al., 1999]. The antineoplastic activity of 
FUdR is believed to be primarily due to inhibition of DNA biosynthesis by blocking 
thymidylate synthase {TS), the enzyme which catalyzes the methylation of 2'-
deoxyuridine-5'monophosphate to thymidine-5'-monophosphate. FUdR must be 
phosphorylated intracellularly to afford 5-fluoro-2'-deoxyuridine-5'-monophosphate 
(FdUMP), a specific competitive inhibitor for TS, to exert its cytotoxic effect 
[Langenbach et al., 1972; Santi et al., 1974]. In addition, FUdR can also exert cytotoxic 
effects by incorporating into DNA or RNA following phosphorylation [Kufe et al., 1981 ]. 
However, this drug suffers from a number of disadvantages which include high toxicity to 
normal tissues, rapid blood clearance, low in vivo efficacy, and drug resistance; 
Resistance of human tumor cells to FUdR is thought to be mainly Via amplification of TS 
mRNA and/or increase in TS activity [Murakami et al., 2000], and it can also result from 
the depletion of activating kinases and uridine phosporylase [Xia et al., 1999]. 
Different strategies have been studied with an attempt to circumvent the above 
problems, such as chemical modification [Guo et al., 1995; Xia et al., 1999], preparation 
of suspension in an oil-water mixture [Ishikawa et al., 1992], and encapsulation iii 
liposomes [Van Borssum Waalkes et al., 1998]. In this study, an alternative strategy, 
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using LDL as a tumor-targeting carrier for FUdR, was investigated. FUd.R was first 
chemically modified to its lipophilic prodrug, 3',5'-dipalmitoyl-FUd.R (dpFUdR) in order 
to achieve the desired incorporation into LDL. dpFUdR was then incorporated into LDL, 
resulting in LDL-dpFUd.R. The antiproliferative effect of LDL-dpFUdR complex was 
studied in human cervical cancer cells with acquired FUd.R resistance. The underlying 
interaction between FUdR and cell TS protein was also examined. 
4.2 Materials and methods 
4.2.1 Materials 
FUdR (Floxuridine) was purchased from Sigma-Aldrich Canada Ltd. (Oakville, 
ON, Canada). Seal oil was provided by Terra Nova Fishery (NL, Canada). The 
antibodies used in flow cytometry analysis were LDL-R (Ab-1), a monoclonal anti-
hLDLR antiboby (primary antibody, from Oncogene, Cambridge, MA, USA), and 
fluorescein isothiocyanate (FITC) or R-phycoerythrin (PE) labeled goat F(ab')2 anti-
mouse IgG (H+L) (secondary antibody, from Cedarlane Laboratories Limited, Hornby, 
ON, Canada). An enhanced chemiluminescence (ECL) detection kit for Western blotting · 
was obtained from Amersham Biosciences, Inc. (Quebec, Canada). Anti-human 
thymidylate synthase (sheep) antibody and peroxidase conjugated affinity purified anti-
sheep IgG [H&L] (rabbit) were purchased from Rockland Inc. (Gibertsville, PA, USA). 
All other chemicals and solvents were obtained from Sigma-Aldrich unless otherwise 
indicated. 
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Silica gel TLC plates with aluminum backing were obtained from Fisher Scientific 
(Ottawa, ON, Canada). High performance liquid chromatography (HPLC) analyses were 
carried out using an HP Series 1050 system (Agilent Technologies, Wilmington, DE, 
USA) with a Phenomenex Bondclone 10 C18, 150 x 3.9 mm column (Torrance, CA, 
USA). A Mini-PROTE~ IT Electrophoresis Cell and a Mini Trans-Blot® 
Electrophoretic Transfer Cell (Bio-Rad Laboratories Ltd., Mississauga, ON, Canada) 
were used to perform SDS-PAGE and protein transfer, respectively. EM examination 
was executed by a JOEL 1200EX electron microscope, during which the samples were 
stained with 1% phosphotungstic acid. 
4.2.21solation ofLDL 
LDL (d = 1.019-1.063 g/ml) was isolated from normolipidemic human plasma 
(Canadian Red Cross, St. John's, NL, Canada) by sequential ultracentifugation 
[Schumaker and Puppione, 1986] using a Beckman L8-M ultracentrifuge and 60/75 Ti 
rotors. The LDL fraction was dialysed at 4°C overnight against a buffer containing 0.3 
mM EDT A, 150 mM NaCl and 50 mM Tris (pH 7.4) and then filtered through a Millex-
GP filter (pore size 0.22 JJ.m, Millipore Co., Billerica, MA, USA). Protein concentration 
of the LDL was determined by the method of Bradford using Bio-Rad protein assay kit 
with.BSA as the standard. The LDL (1.6-2.2 mg/ml) was stored at 4°C under argon and 
used for experiments within 2 weeks. 
4.2.3 Preparation of LDL-dpFUdR complex 
As illustrated in Figure 4.1, 3',5'-dipalmitoyl-FUdR was synthesized by the 
reaction of FUdR in dry dichloromethane with palmitic acid according to the published 
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method [Schwendener et al., 1985; Van Borssum Waalkes et al., 1993]. The purity of 
dpFUdR was checked by TLC and reverse-phase HPLC. To prepare LDL-dpFUdR, 
dpFUdR emulsion was first prepared using the method reported previously [Xiao1 et al., 
1999]. Twelve milligram of PC, 8mg ofDPPE, 20 mg of seal oil and 10 mg of dpFUdR 
were dissolved in chloroform, dried under a nitrogen flow and re-suspended in 10 ml of 
saline. The suspension was sonicated for 2 h at 0°C and centrifuged at 40,000 rpm 
(Beckman L8-M ultracentrifuge) for 7 h at 4°C. The floating emulsion fraction was 
collected and then incubated with LDL at 37°C for 8 hat a dpFUdR to LDL molar ratio 
of 1000:1, following which dpFUdR-LDL complex was purified by ultracentrifugation. 
To determine its concentration, dpFUdR incorporated into LDL was extracted by 
chloroform and immediately subjected to HPLC. 
To assess and compare the integrity of apoB-100 in native LDL with that loaded 
with dpFUdR, 8% SDS-P AGE was performed and the separating gel was stained with 
Coomassie blue R250 (Bio-Rad) to visualize the resultant protein band. The effect of 
loading dpFUdR on the morphology ofLDL particles was analyzed by EM. 
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H3C-(CH2)14-C-QH 
2 
1. 5-Fluoro-2'-deoxyuridine (FUdR) 
2. Palmitic acid 
3. 3' ,5'-Dipalmitoyl-5-fluoro-2'-deoxyuridine (dpFUdR) 
DCC: Dicyclohexylcarbodiimide 
DMAP: Dimethylaminopyridine 
CH2Ch: Dichloromethane 
3 
Figure 4.1. Scheme of the synthesis of 3',5'-dipalmitoyl-5-fluoro-2'-
deoxyuridine (dpFUdR). 
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4.2.4 Cell culture 
Several human cancer cell lines including cervical cancer cells (Hela and Siha) and 
breast cancer cells (MCF7, BT20, and ZR751) were generously provided by Dr. A. Pater 
(Faculty of Medicine, Memorial University of Newfoundland) and maintained in DMEM 
that was supplemented with 10% FBS, 100 IU/ml penicillin and 100 mg/ml streptomycin 
at 37°C, 5% C02. The logarithmically growing cells were harvested by trypsinization 
and used for the experiments described below. Cell number was counted with a 
hemocytometer. 
4.2.5 Determination of LDLR level on cell surface 
Flow cytometry analysis was used to evaluate the LDLR level on the cell surface of 
the above cultured cell lines. Briefly, each type of cells was harvested and washed with 
ice-cold PBS, following which approximately 1.5 x 105 cells were incubated with 0.1 J.Lg 
of monoclonal anti-hLDLR antiboby (primary antibody) in 25 J.1l of PBS at 4°C for 30 
min.· After washing 2 times by large volume of PBS (1.3 ml), the cells were stained by 
FITC or PE-conjugated goat anti-mouse IgG (secondary antibody, 0.7 J.Lg/50 J.Ll PBS) at 
4°C for 30 min. The washed cells were then fixed in 200 J.Ll of 1% paraformaldehyde-
PBS and subsequently examined by F ACS Star® -Plus flow cytometer (Becton Dickinson, 
Palo Alto, CA, USA). As controls, cells were either unstained during the whole 
procedure or probed with PBS instead of the primary antibody and then incubated with 
FITC/PE-conjugated secondary antibody. 
4.2.6 Establishment of FUdR-resistant Bela cells 
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A FUdR resistant subline of Hela, Hela/FUdRr, was developed according to a 
published method with minor modifications [Murakami et al., 2000]. In brief, Hela cells 
were cultured until 80-90% confluence, at which time point the medium was changed to 
DMEM containing 1 J!M FUdR. After a 3-day exposure, the cells were cultured in drug-
free medium again until the surviving cells re-grew. These cells were then repeatedly 
exposed for 3 days to step-wise increasing concentrations ofFUdR up to 60 J!M. FUdR-
resistant Hela cells were established by this process over about 6 months and named as 
Hela/FUdRr cells. 
4.2. 7 Cytotoxicity assessment by MTT assay 
The MIT assay for evaluation of drug cytotoxicity is based on the mitochondrial 
reduction of a yellow tetrazolium compound, 3-[4,5-Dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MIT), to a colored formazan product (Mosmann, 1983; 
Cole, 1986; Sladowski et al., 1993). In brief: Hela or Hela/FUdRr cells in fresh DMEM 
were seeded into 96-well flat-bottomed plates (Coming Incorporated., Coming, NY, 
USA) in a volume of 100 JLl at 1x104 cells/well using a multichannel pipette (BrandTech 
Scientific, Inc., Essex, CT, USA). The plates were incubated at 37°C for 12 h to allow 
cells to re-attach and re-equilibrate. The cells were then exposed to various 
concentrations of LDL-dpFUdR or FUdR (in PBS) prepared by 2 time series dilution for 
48 h with equal amounts of dpFUdR emulsion and native LDL as control. Subsequently, 
most medium was removed from each well and 50 JLl of MIT solution (2 mglml in PBS) 
were added. After 4 h of incubation at 37°C, the supernatant was carefully sucked off, 
and 100 JLllwell of dimethylsulfoxide (DMSO) was added to solubilize the formazan 
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metabolite. Following a brief shaking, the plates were read at wavelength 595 nm in a 
microplate reader (Bio-Rad, Model 550). Usually four to five replicate wells were used 
for each group to be tested, and each experiment was repeated at least twice. Controls 
included wells with cells but no drugs and wells with medium and the highest drug 
concentration but no cells. 
4.2.8 Western blotting analysis 
Hela or Hela/FUdRr cells, before and after 24 h exposure to 10 J.LM FUdR or LDL-
dpFUdR, were lysed in a lysis buffer (0.5% Triton X-100, 1mM CDTA, 1 mM PMSF, 1 
mglml aprotinin, 20 mM MOPS, pH 7.2) for 30 min on ice, followed by centrifugation at 
14,000 g for 15 min. Extracts ( 40 J.Lg protein) were mixed with 4 x SDS sample buffer 
containing 1% 2-mercaptoethanol and heated at 95°C for 5 min before loading onto a 
12% discontinuous SDS polyacrylamide gel. The transfer of proteins to nitrocellulose 
membranes (Hybond® ECL, from Amersham) was carried out at 100 V for 2 h in a 
transfer buffer prepared according to the protocol of Bio-Rad. The membranes were 
washed twice in TBST (10 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20, pH 8) and 
then blocked with 1% BSA-TBST for 45-60 min. Primary antibody, sheep anti-human 
TS, was diluted in TBST and incubated with the membranes overnight at 4°C. After 
washing, the membranes were incubated for 1 h with secondary antibody (horseradish 
peroxidase (HRP)-conjugated rabbit anti-sheep lgG) diluted 1:1000 in TBST and then 
washed again. The detection of protein bands were accomplished using ECL kit as 
described in Amersham's instruction. The results were analyzed by densitometric 
scanning using a Chemilmager™ (Alpha Innotech Corporation, San Leandro, CA, USA). 
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4.3 Results and discussion 
The feasibility of chemotherapy in which native LDL loaded with cytotoxic drug is 
used to inhibit tumors expressing the LDLR had been explored extensively [Firestone, 
1994; Filipowska et al., 1992; De Smidt and Van Berkel, 1990]. LDL is a kind of 
quasispherical endogenous nanoparticle with a long serwn half-life of2-4 days in humans, 
which provide a further possibility of an increased therapeutic effect of the cytotoxic drug 
loaded into LDL due to its prolonged circulation time compared to that of the free drug. 
FUdR is a water-soluble nucleoside analogue which is effective in the treatment of 
certain human epithelial tumors. Its activity is up to 100 times higher than that of the 
parent compound 5-fl.uorouracil (5-FU) on a molar basis in in vitro test. In in vivo studies, 
however, FUdR has been reported to be less potent than 5-FU [Heidelberger et al., 1958; 
Laskin et al., 1976]. Considering the fast degradation rate ofFUdR and the fact that the 
cytotoxicity of FUdR largely depends on the duration of its exposure to tumor cells 
[Kanzawa et al., 1980; Yin et al., 1991], it may be postulated that the incorporation of 
FUdR into LDL should improve its cytotoxic effect by altering its pharmacokinetic 
properties accompanied by the more specific tumor delivery. The lipid fractions of LDL 
allow a substantial quantity of lipophilic drug( s) to be stored inside. Therefore, a diester 
prodrug of FUdR, dpFUdR, was synthesized in the present work. dpFUdR is highly 
lipophilic and should be a better candidate for the incorporation into LDL than 
hydrophilic FUdR. The design of an esterified prodrug is a common strategy to improve 
the lipophilicity and pharmacokinetic/pharmacodynamic properties of the drugs 
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containing a carboxyl or hydroxyl group, since the human body is rich in esterases which 
are capable of hydrolyzing ester prodrugs and releasing the active prodrug moieties 
[Bundgaard, 1991 ]. 
4.3.1 Characterization ofLDL-dpFUdR complex 
The incorporation of dpFUdR into LDL was achieved using a method established 
in our lab through the incubation of dpFUdR-seal oil emulsion and LDL. The 
concentration of dpFUdR loaded in LDL was measured by HPLC after dpFUdR was 
recovered by chloroform extraction from LDL-dpFUdR complex. As shown in Figure 
4.2, HPLC was performed using a mobile phase of methanol (MeOH) : H20 (98:2, v/v) at 
a flow rate of 1 ml/min in conjunction with a UV detector (268 nm) and the retention time 
of dpFUdR was 9 min. According to the calculation of both drug and LDL protein 
concentration, it was found that there were approximately 220 dpFUdR molecules 
conjugated with one LDL particle. To characterize the integrity of apoB-100 and 
probably the whole LDL particle, LDL-dpFUdR was compared with native LDL using 
SDS-P AGE and EM examination, respectively. As can be seen in the result of 8% SDS"' 
PAGE (Figure 4.3), there was only one stained band equivalent to the size of apoB-1 00 in 
both lanes, and neither had degradation products. EM photographs (Figure 4.4) also 
showed particles similar in morphology, as well the size for both samples. The abbve 
results indicate that the incorporation of dpFUdR did not alter the integrity of LDL, and 
the apoB-1 00 remained intact. The latter is thought to be crucial for the recognition of 
the particles by LDLR on the cell surface. 
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A. 
B. 
Mobile phase: MeOH: H20 
98:2 (v/v) 
Flow rate: 1 ml/min 
Detector: UV, 268 nm 
(reference 450 nm) 
Injection: 10 J.ll, -0.15 mg/ml 
Figure 4.2. Chromatograms of dpFUdR in mobile phase using HPLC. (A) 
dpFUdR standard in mobile phase; (B) dpFUdR extracted from LDL-
dpFUdR complex. 
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31 
LDL-dpFUdR LDL 
Figure 4.3. 8% SDS-P AGE of LDL-dpFUdR complex and native LDL. 
Approximately 0.5-1 J.Lg protein was loaded for each sample and 
electrophoresed at 200 V for 40 min. The separating gel was stained with 
Coomassie blue R250. The positions of a broad range of molecular weight 
standard (x kDa) are shown with arrow marks. 
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A. LDL {75,000x3 x) B. LDL-dpFUdR (79,800x3 x) 
Figure 4.4. Electron micrographs (3x) of LDL and LDL-dpFUdR 
preparations. The samples (10-20 J..lg proteinlml) were applied to formvar 
and carbon-coated copper grids and negatively stained with , l% 
phosphotungstate solution, followed by examination using a JOEL 1200EX 
electron microscope at a magnification of 75,000 x or 79,800 x. (A) native 
LDL; (B) LDL-dpFUdR. The bar represents 50 nm. 
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4.3.2 Evaluation of cell swiace LDLR level 
Several human cancer cell lines were stained with monoclonal anti-hLDLR 
antibody and analyzed by flow cytometry. Figure 4.5 demonstrates the result from Hela 
cells. As can been seen, cell numbers (counts) were plotted against the log of 
fluorescence intensity (PE-Height) and the histogram of Hela cells stained with anti-
hLDLR antibody (red color) was overlaid on those of control cells (non-stained cells and 
cells incubated with only secondary antibody but no anti-hLDLR antibody, green and 
black color respectively). The right shift indicates the expression of LDLR on the cell 
surface. The histograms of other cell lines showed similar pattern as that of Hela cells, 
whereas the shift was less. The Hela cell was then considered to possess the highest level 
of LDLR among these cell lines when tested by this method, and therefore a good 
candidate for the LDL-mediated cell-specific targeting of antiproliferative drugs. In the 
subsequent experiments, the Hela cell line was chosen to develop the acquired FUdR-
resistant subline. 
It has to be pointed out that, unlike the classical binding assay using radioiodine-
labeled LDL [Goldstein and Brown, 1974; Xiao3 et al., 1999], the flow cytometty 
analysis used in this experiment could not quantify the absolute receptor amount on cell 
surface. However, it is a simple and fast means to screen or compare the LDLR level of 
different cell lines without a need to manipulate radioisotope. 
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Mean value of fluorescence intensity 
Red 32.97 
Black 10.10 
Green 8.06 
102 10;) 
Figure 4.5. Flow cytometry analysis of LDLR level on the surface of Hela 
cells. The histogram of Hela cells stained with monoclonal anti-hLDLR 
antibody (red line) was overlaid on the histograms of controls: non-stained 
cells (green line) and cells stained with only secondary antibody (black line). 
Cell numbers (counts) are plotted against the log of fluorescence intensity 
(PE-Height). The number inside the panel indicates the mean values. 
97 
4.3.3 Cytotoxicity assay 
Human cervical cancer cells with acquired resistance to FUdR, referred here as 
Hela/FUdRr cells, were established by step-wise exposure of Hela cells to FUd.R. As 
shown in Figure 4.6A, 4.6B, and Table 4.1, Hela/FUdRr cells were proved to be relatively 
FUd.R-resistant. After 48 h exposure, the ICso value ofFUdR was 8.9 J.1M against Hela 
cells, and approximately 10% cells were found to be able to survive from a high 
concentration of FUdR (150 JlM); whereas in Hela/FUdRr cells, the ICso of FUd.R was 
more than 2 times higher (20.2 J.1M) and up to 30% cells still remained resistant to 150 
J.1M ofFUd.R. 
dpFUdR, a prodrug of FUdR, was prepared as a emulsion formulation and 
subsequently incorporated into LDL, resulting in LDL-dpFUd.R complex. Cytotoxic 
effects of LDL-dpFUdR versus free FUdR or dpFUdR emulsion on Hela and Hela/FUdRr 
cells after 48 h treatment were evaluated by MTT assay and illustrated in Figure 4.6 and 
Table 4.1. In Hela cells, LDL-dpFUdR showed an ICso value of 7.5 J.1M after 48 h 
exposure, indicating an equivalent toxicity as the parent drug, FUd.R (ICso 8.9 JlM). 
Nevertheless, at the concentration of 21 JJM, LDL-dpFUdR was capable of inducing 
100% cell death. In Hela/FUdRr cells, LDL-dpFUdR resulted in similar results as in Hela 
cells with an IC50 value of 4.7 fJM and also a completed toxicity at the concentration of21 
fJM. However, when compared to FUdR, LDL-dpFUdR demonstrated a 5-fold lower 
IC50 value (4.7 fJM versus 20.2 JlM), indicating an increased cytotoxic effect of LDL-
dpFUdR in FUdR resistant cells. On the other hand, dpFUd.R emulsion presented 5-7 
fold lower toxicity, as revealed by the IC5o values, than LDL-dpFUd.R in both cells, and 
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LDL itself did not show any contribution to the toxicity of LDL-dpFUdR in. all 
experiments. 
Since the loading of the prodrug into LDL did not influence the integrity of apoB-
1 00, it was believed that the internalization of LDL-dpFUdR complex by Hela or 
Hela/FUdRr cells was mainly via LDL receptor-mediated process instead of a simple 
diffusion [Xiao3 et al., 1999; Westesen et al., 1995; Masquelier et al., 1986]. Compared 
with dpFUdR emulsion, LDL carried dpFUdR resulted in an increased cytotoxicity in 
both cell types, implying a targetted delivery and enhanced uptake through the LDLR 
pathway. Although LDL-dpFUdR did not lead to higher toxicity than free FUdR in Hela 
cells according to the ICso value, it could overcome the FUdR resistance of Hela cells, 
which was encountered when using FUdR. This advantage of LDL-dpFUdR complex 
was further demonstrated in drug-resistant Hela/FUdRr cells by its decreased ICso value 
compared to FUdR and 100% toxicity at a relatively lower concentration. 
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Figure 4.6A. Cytotoxic effect on human cervical Hela cells after 48 h 
exposure to various concentrations of FUdR, LDL-dpFUdR complex, 
dpFUdR emulsion and LDL (control). Cells were subjected to the MTT 
assay. The results are represented as the average ± SE from three 
independent experiments. 
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Figure 4.6B. Cytotoxic effect on FUdR-resistant Hela/FUdRr cells after 48 
h exposure to various concentrations of FUdR, LDL-dpFUdR complex, 
dpFUdR emulsion and LDL (control). Cells were subjected to the MTT 
assay. The results are represented as the average ± SE from three 
independent experiments. 
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Table 4.1. Concentrations of FUdR, LDL-dpFUdR complex and dpFUdR 
emulsion to cause a 50% inhibition of the growth of Hela or Hela/FUdRr 
cells after 48 h exposure 
Cells 
Hela 
Hela/FUdRr 
ICso {J1M) 
FUdR (in PBS) LDL-dpFUdR dpFUdR emulsion 
8.9 
20.2 
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7.5 
4.7 
39.3 
33.3 
It should also be noted that, there was a "concentration threshold" [Kawaguchi 1 et 
al., 1985] for the cytocoxicity of the prodrug, dpFUdR, in both Hela and Hela/FUdRr 
cells based on the MTT results regardless of its formulation, either incorporated into LDL 
or prepared as an emulsion. When the concentration is lower than ''threshold", the cell 
growth inhibition potency of LDL-dpFUd.R or dpFUd.R emulsion appears similar to that 
of FUdR. However, after the concentration exceeds the ''threshold", both dpFUdR 
formulations significantly enhance the cytotoxicity as indicated by a decrease of cell 
growth curve slope. In all cases, FUd.R retained the gentle slope without considerable 
change over a wide range of concentrations, implying that FUd.R could not kill all of the 
cells due to drug resistance. Possible explanations for this observation might be the fact 
that the hydrolytic rate of the prodrug, dpFUdR, by the cytoplasmic enzyme was slow at 
the low concentration of prodrug and high at its high concentration [Kawaguchi2 et' al~, 
1985]. 
4.3.4 TS level in cells analyzed by Western blotting 
TS is a key regulatory enzyme that catalyzes the methylation of deoxyuridine 
monophosphate in the de novo pathway of pyrimidine synthesis. It is known that TS 1s 
also an important cellular target for fluoropyrimidine cytotoxic drugs such as FUd.R. 
Intracellularly, FUd.R is converted to FdUMP, which inhibits TS by forming a stable 
ternary complex with methylene tetrahydrofolate (CH2THF), leading to cytotoxicity 
[Drake et al., 1993]. One of the main reasons of FUd.R resistance is reported to be 
increased TS activity and/or TS overproduction. Quantitation of TS protein level has 
been carried out by clinics to prognose cancer activity and the resistance of malignant 
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tumor to anticancer drugs such as 5-FU and FUdR [Kuniyasu et al., 1998]. Measurement 
of TS includes eH]-FdUMP binding assay, enzyme activity assessment, as well as the 
polymerase chain reaction based procedure which determines the level of TS mRNA 
[Suzuki et al., 1998]. In this study, Western blotting was used to analyze TS levels in 
Hela and Hela/FUdRr cells before or after FUdR treatment, and a newly developed 
polyclonal antiserum that is highly specific for TS, and at the same time could recognize a 
broad range of epitopes, was chosen to probe TS signal [Haqqani et al., 1999]. 
. As shown in Figure 4. 7, the 36 kDa band was recognized as TS, while the shifting 
band (38.5 kDa) represented the ternary complex (TS + FUdR metabolite + CH2 THF), 
which migrates more slowly. In the absence of drug treatment, only TS bands were 
observed in both Hela and Hela/FUdRr cell extracts (see lane 1 and 2), and the IEittet 
showed a relatively denser band (96 vs. 76 as quantitated by densitometric scanning), 
suggesting a slightly higher TS level in Hela/FUdRr cells. Although the increase of TS 
expression in Hela/FUdRr cell is not obvious in comparison to Hela cell, as revealed in 
this analysis, the result indicated the trend ofTS overexpression in FUdR-resistant cells; 
After 24 h of FUdR or LDL-FUdR exposure, two bands were observed for each sample: 
the TS band and the ternary complex band. It was found that there was no distinct 
difference in the density of the corresponding bands. However, a trend could also be 
detected that LDL-dpFUdR led to a denser complex band than FUdR in Hela/FUdRr cells 
(lane 3 and 4), indicating that more dpFUdR molecules were transported into FUdR• 
resistant cells by LDL and subsequently hydrolyzed to free FUdR. This is presumed to be 
the mechanism for LDL-dpFUdR to overcome the acquired FUdR-resistance of cancer 
cells. In Hela cells (lane 5 and 6), on the other hand, LDL-dpFUdR resulted in an 
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equivalently dense complex band as FUdR, which is also matching the MTI result, that 
is, the cytotoxicity ofLDL-dpFUdR and free FUdR were similar. 
In summary, FUdR is a highly potent antiproliferative compound in in vitro test, 
and its lipophilic ester prodrug, dpFUdR, can be converted to FUdR by intracellular 
hydrolysis to execute the cytotoxic effect. When incorporated into LDL, dpFUdR could 
be more actively taken up by human cervical cancer cells (Hela) via the LDL receptor-
mediated pathway. In comparison with the parent drug, FUdR, LDL-dpFUdR was also 
found to be able to overcome the acquired FUdR-resistance. Although LDL has not been 
paid the same attention as a tumor targeting vehicle in chemotherapy compared to years 
ago, it remains as a potential carrier for some anti-cancer drugs. 
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LDL-dpFUdR - + + 
38.5kDa 
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Figure 4.7. Western blotting analysis of TS level in Hela or Hela/FUdRr 
cells before and after 24 h treatment with 10 fJ.M FUdR and LDL-dpFUdR. 
The result shown here is a representive of three independent experiments. 
The 36 kDa band was recognized as TS, while the shifting band (38.5 kDa) 
represented the ternary complex (TS + FUdR metabolite+ CH2THF), which 
migrates more slowly. Without drug treatment, only TS bands were . ': 
observed, and Hela/FUdRr cells showed a relatively denser band than Hela 
cells, indicating a slightly higher TS level (lane 1 and 2). After drug 
exposure, two bands were observed for each sample, and there was no. 
distinct difference in the density of the corresponding bands (lane 3, 4 and 5, 
6). 
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Chapter 5. Summary 
Targeting delivery of pharmaceuticals has been a long-term research interest in the 
field of pharmacy. Many different types of delivery system have been explored, ranging 
from numerous synthetic carriers (e.g. emulsions, liposomes, microspheres) through to 
naturally occurring materials such as lipoproteins and viruses. These approaches have 
been extensively investigated in attempts to reduce the risk of cardiovascular diseases. In 
the work of this thesis, modified LDL was evaluated as a selective carrier of a 
radioimaging agent for the diagnosis of atherosclerosis. A liver-targeting liposome 
formulation was also developed with an ultimate objective of delivering therapeutical 
gene in the treatment ofFH, a prevalent genetic disorder leading to atherosclerosis. 
LDL is the main lipoprotein particle responsible for the transportation of 
cholesterol in the plasma. It had been demonstrated to have a close relationship with the 
development of atherosclerosis due to the fact that continuous deposition of Li>L 
cholesterol in the artery wall contributes to the formation as well as the growth of 
atherosclerotic lesions. In the development of malignant tumors, LDL also plays ·an 
important role because numerous cancer cells presumably need much cholesterol from 
LDL to meet the requirement for their proliferations. LDL is taken up by cells mainly via 
a specific receptor-mediated process, which provides a rational to use naturally originated 
LDL as a targeting carrier for compounds to the cells expressing high level of tor..: 
receptors. 
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In chapter 2, one of the main parts of the thesis, a radioimaging agent for detection 
of early atherosclerosis was evaluated by incorporation of a non-hydrolyzable radiotracer, 
C2I, into AcLDL, a modified form of LDL. Our results demonstrated the great potential 
of the C2I/AcLDL agent for imaging atherosclerotic lesions. Besides its diagnostic usage, 
LDL was also examined as a delivery system for an antiproliferative drug in cancer 
chemotherapy. As described in chapter 4, the prodrug, dpFUdR, was successfully 
conjugated with LDL, and LDL-dpFUdR, compared to free FUdR, resulted in 
overcoming the acquired FUdR resistance of human cervical cancer cells. 
As a type of synthetic carrier, cationic liposome is one of the most promising 
vehicles used in the area of gene therapy. The second objective of the thesis was to 
develop a liver-targeting liposome-DNA complex for the purpose of correcting LDLR 
deficiency of FH model. Chapter 3 summarized the experiments conducted so far which 
were concentrated on in vitro studies. A malaria peptide derivative conjugated LPD 
formulation was developed and showed encouraging, however, somewhat inconsistent, 
transfection results in human hepatoma cells. 
On the basis of results in this thesis, further studies will be performed: (1) using 
other radionuclides, such as 1311, and other atherosclerotic animal models, such as mini-
pig to study the blood clearance profile ofC21/AcLDL and image atherosclerosis in vivo; 
(2) to modify the malaria peptide derivative, optimize the preparation condition of the 
peptide-LPD complex and examine the in vivo behaviour of the formulation. 
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